 
 
    
 
Renal Allograft Tolerance Through Mixed Chimerism  
 
 
Version 3.0 (January 27, 2014 ) 
     
Co-Principal Investigator:  
 
A.Benedict Cosimi, MD  
David H. Sachs, MD  
Tatsuo Kawai, MD, PhD  
 
Coinvestigators:  
 
James Markmann, MD, PhD 
Nina Tolkoff-Rubin, MD  
Thoma s Spitzer, MD  
Robert B Colvin, MD  
Rex- Neal Smith, MD  
Susan Saidman, PhD  
Joren Madsen, MD, D.Phil.  
Jay Fishman, MD  
Nahel Elias, MD  
Winfred Williams, MD  
Yi-Bin Chen, MD  
Bimal Dey, MD  
Steve McAfee, MD  
Karen Winkfield , M.D. Ph.D. 
Fred Preffer, PhD  
Gilles Benic hou, PhD  
   
Study Coordinator  
Kerry Crisalli, RN  
 
 
 
 
 1 
 
Synopsis  
 
Title    Renal Allograft Tolerance Through Mixed Chimerism  
 Short Title   Renal Allograft Tolerance  
 IND Sponsor   David H Sachs  
 IND #    BB- IND 10181  
 Trial Phase   Phase I /II 
 Conducted by   MGH, Transplant Surgery  
 Principal Investigators  A. Benedict Cosimi, MD     
David H Sachs, MD  
Tatsuo Kawai, MD, PhD  
 
Accrual Objective  2 participants with end -stage renal disease (ESRD) and no evidence of prior 
sensitization, and their donors  
 Study Design   P ilot study  
 Pace of Enrollment  Enrollment will be limited to one patient  every  three months   
and Study Duration    
  
Participants will be followed for a total of 5 years after combined bone marrow 
and kidney transplantation.  Assessments will be performed for participant and 
graft survival, and long term adverse events.  
 Endpoint  The primary endpoint  is Induction of transient mixed chimerism and renal 
allograft tolerance without “engraftment syndrome” or “acute kidney injury”.  
   
Recipient Inclusion Criteria   
 
1.   Male or female 18 –60 years of age.  
 2.   Candidate for a living -donor renal allograft with a one haplotype identical donor identified.  
 3.   First or second transplant with either a living donor or cadaveric transplant as the first transplant.  
 4.   Use of FDA -approved methods of contraception (those with less than a 3% failure rate) by all 
recipients from the time that study treatment begins until 104 weeks (24 months) after renal 
transplantation. (For further information on FDA - approved methods  of contraception, see  
http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118465.htm  
 
 2 
 
5. Ability to understand and provide informed consent.  
 
6. Serologic evidence of prior e xposure to EBV.  
  
Recipient Exclusion Criteria  
 
1. ABO blood group -incompatible renal allograft.  
 
2. Evidence of anti -HLA antibody within 60 days prior to transplant as assessed by  routine 
methodology (AHG and/or ELISA)   
 
3. Leukopenia (WBC less than 2,000/mm3) or  thrombocytopenia.  
 
4. Seropositivity for HIV- 1, hepatitis B core antigen, or hepatitis C virus (confirmed by hepatitis C     
virus RNA); or positivity for hepatitis B surface antigen.  
 
5. Cardiac ejection fraction < 40% or clinical evidence of insufficiency.  
 
6. Forced expiratory volume FEV1 < 50% of predicted.  
 
7. Lactation or pregnancy.  
 
8. History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix.  
 
9. Underlying renal disease etiology with a high risk of disease recurrence in the  transplanted 
kidney (such as focal segmental glomerulosclerosis, type I or II membranoprolifertive glomerulonephritis).  
 
10. Prior dose -limiting radiation therapy.  
 11. Known genetic disease or family history that may result in greater sensitivity to the effects  of 
irradiation, or a physical deformity that would preclude adequate shielding or appropriate dosing during the irradiation component of the conditioning regimen.  
 
12. Enrollment in other investigational drug studies within 30 days prior to enrollment.  
 
13.  Abno rmal (>2 times lab normal) values for (a) liver function chemistries (ALT, AST, AP), (b) 
bilirubin, (c) coagulation studies (PT, PTT).  
 14.  Allergy or sensitivity to any component of MEDI -507, tacrolimus, or rituximab. 
 15. Maintenance immunosuppression within 3 months prior to conditioning other than physiological doses of steroids, defined as ≤ 50 mg of hydrocortisone or dose equivalent.  
 
16. The presence of any medical condition that the investigator deems incompatible with 
participation in the trial.  
 
 3 
 
Donor Inclusion Criteria  
  
1.  Male or female 18 –65 years of age.  
 
 2.   For females of childbearing potential: a serum pregnancy test showing negative results.  
 
3. Excellent health per conventional predonor history (medical and psychosocial evaluation).  
 
4.  Acceptable laboratory parameters (hematology in normal or near- normal range; liver 
function <2 times the upper limit of normal, and normal creatinine).  
 
5.   Negative for viral infection with HbsAg, HIV, HCV, or HTLV -1. 
 
6.   Cardiac/pulmonary function within normal limits (CXR, ECG).  
 
7. Ability to understand and provide informed consent.  
 
8. Meets standard institutional criteria for both bone marrow and kidney donation  
 
Treatment Description   
Recipients will receive a conditioning regimen that starts with Rituximab on day – 7 (and 
days –2, 5, 12), Whole Body Irradiation 150 c Gy x2  on study days –5 and –4, followed by 
MEDI -507, a T -cell-depleting agent, will be administered on days – 2, –1, 0, and 1. Thymic 
irradiation (7 00 cGy) will be given on study day – 1, and combined renal and bone 
marrow transplant will be done on study day 0. Prednisone  will be started at 2 mg/kg on 
day 4 and tapered off by day 20. Tacrolimus will be administered on study days –1 
through 60, and then tapered if weaning criteria are met. Leukapheresis will be performed prior to initiating the conditioning regimen and thes e cells will be frozen 
 All patients who require a blood transfusion will receive only leukocyte -depleted and 
irradiated blood products for a period of at least 52 weeks following transplantation.  
 The proportion of patients not suffering “engraftment syndrome” and successfully weaned off immunosuppression will be assessed.  
      
    
 
  
 4 
 
Glossary of Abbreviations  
 
AHR   acute humoral rejection  
ALC  absolute lymphocyte count  
ANC   absolute neutrophil count  
APC  Antigen -presenting cell(s)  
ATG   antithymocyte  globulin  
ATGAM   lymphocyte immune globulin  
ATN   acute tubular necrosis  
BMT  bone marrow transplantation  
CBC  complete blood count  
CFR  Code of Federal Regulations  
CKBMT   Combined kidney and bone marrow transplant  
CIS  carcinoma in situ  
CML   cell-mediated  lysis, cell- mediated lympholysis  
CMV   cytomegalovirus  
CRF  case report form  
CTCAE   Common Terminology Criteria for Adverse Events  
CTL  cytotoxic T lymphocyte  
CVVH   continuous veno venous hemodialysis  
ELISA  enzyme -linked immunosorbant assay  
ELISPOT  enzy me-linked immunospot (assay)  
ESRD   end- stage renal disease  
GVHD   graft -versus -host disease  
GCP  Good Clinical Practice  
HLA  human leukocyte antigen  
HTL  helper T lymphocyte  
ICH  International Conference on Harmonisation  
IND  investigational new drug  
IRB  institutional review board  
ITN  Immune Tolerance Network  
LDA  limiting dilution analysis  
MGH  Massachusetts General Hospital 
MHC   major histocompatibility complex  
MLR   mixed lymphocyte response, mixed lymphocyte reaction  
NCI-CTCAE  National Cancer Ins titute- Common Terminology Criteria for Adverse Events  
NK  natural killer (cell)  
PBMC   peripheral blood mononuclear cell(s)  
PCP  Pneumosystis carinii pneumonia  
PRA  panel -reactive antibody; panel reactivity assay  
PTLD   post -transplant lymphoproliferative disease  
RTEC   renal tubular epithelial cell(s)  
RT-PCR  real- time polymerase chain reaction  
SAE  serious adverse event  
SAEC   safety adverse event coordinator  
SAP  statistical analysis plan  
SI  Stimulation Index  
TBI  total body irradiation  
 5 
 
TI  thymic irrad iation  
TREC   T- cell receptor excision circle(s)  
Treg   regulatory T cell  
 
 
 
         
 
         
 
         
 
         
 
  
 6 
 
 
Table of Contents   
 1. BACKGROUND.........................................................................................................................................1 2 
 
1.1 SUMMARY.............................................................................................................................................1 2 
 
1.2 PRECLINICAL AND CLINICAL STUDIES ....................................... .............................................................15 
 1.2.1 Preclinical Studies ............................................................................................................................ 16 
 1.2.2 Clinical Studies: P rior Studies ........................................................................................................... 16 
 1.3 RISKS TO PARTICIPANTS.......................................................................................................................21  
1.3.1 MEDI -507 ......................................................................................................................................... 21 
 
1.3.2  Rituximab (Rituxan®) ...................................................................................................................... 22 
 1.3.3  Low Dose Total Body Irradiation .................................................................................................... 23 
 1.3.4    Thymic Irradiation ......................................................................................................................... 2 3 
 1.3.5  Tacrolimus............................................................................................................................... ..... 23 
 
1.3.6  Prednisone................................................................................................................................... 23 
 
1.3.7 GVHD ............................................................................. .................................................... .......... 2 4 
 1.3.8 Renal Graft Failure ......................................................... ........................................ .............. ........ 2 4 
 1.3.9 Infection ....................................................................................................................................... 2 4 
 1.3.10 Bone Marrow Transplant -related Mortality............................................................................. .... 2 5 
 
1.3.11 Renal Biopsies .............................................................................................................................. 2 5 
 
1.3.12 Leukapheresis .......................................................................................................................... .... 2 5 
 1.3.13 Engraftment Syndrome ............................................................................................................... 2 5 
 1.3.14   ATG  (Thymoglobulin and ATGAM) ……………………… ……… ..........................………………………………….. 26 
 1.4 RISKS TO DONORS..........................................................................................................................26 
 
1.4.1  Bone Marrow Donation ....................................................................................................... ........ 26 
 
1.4.2  Kidney Donation .......................................................................................................................... 2 7 
 7 
 
 
1.4.3  Combined BMT and Kidney Donation.................. ..........................................................................27 
 1.5 RATIONALE FOR SELECTION OF CONDITIONING REGIMEN..................................................... ......27 
 
2 STUDY DESIGN ..............................................................................................................................28 
 
2.1 DESCRIPTION ................................................................................................................................ .28 
 2.2 CONSENT FOR PARTICIPAT ION.................................................................................................... ..28 
 2.3 STUDY ENDPOINTS ............................................................................................................... .........28 
 2.3.1 Primary Endpoint.......................................................................................................................... 2 8 
 
2.4 STOPPING RULES...........................................................................................................................28  
 
2.4.1 Ongoing Review............................................................................................................................ 28 
 2.4.2 Review of Specific Adverse Events ................................ ............................................................. . 29 
 2.4.3  Data Monitoring Committee ……………… …….....................………………………………………………………….. 29 
 2.5 ENROLLMENT, TIMING OF TRANSPLANT, AND LENGTH OF FOLLOW- UP .....................................29 
 
3 ELIGIBILITY ................................................................................................................. ...................29 
 
3.1 RECIPIENT INCLUSION CRITERIA................................................................................................. ...30 
 3.2 RECIPIENT EXCLUSION CRITERIA ...................................................................................................30 
 3.3 DONOR INCLUSION CRITERIA ......................................................... ...............................................3 1 
 3.4 PREMATURE DISCONTINUATION OF STUDY THERAPY............................................... ...................3 1 
 
3.4.1  Reasons for Premature Discontinuation of Study Therapy........................................................... 3 1 
 
3.4.2  Follow -up for Participants Prematurely Discontinued from Study Therapy................................. 3 2 
 3.5 PREMATURE TERMINATION FROM THE STUDY............................................................................3 3 
 3.5.1  Reasons for Premature Termination from the Study....................................................................33 
 3.5.2  Follow -up for Participants Prematurely Terminated from the Study ...................................... .... 3 3 
 
4 STUDY MEDICATIONS AND PROCEDURES......................................................................................33 
 
4.1 OVERVIEW OF CONDITIONING AND POST TRANSPLANT REGIMEN....................... .......................3 3 
 8 
 
 
4.2 DONOR BONE MARROW HAR VEST AND NEPHRECTOMY.......................................................... ....33 
 4.3 LEUKAPHERESIS ............................................................................................................................34 
 
4.4 CONDITIONING REGIMEN ..............................................................................................................3 4 
 
4.4.1  Rituximab (Days –7, –2, 5, and 12)............................................................................................... 3 4 
 4.4.2 Low dose Total Body Iradiation (Days – 5 and – 4) ...................................................................... .. 35 
 4.4.3  MEDI -507 (Days – 2, -1, 0, and 1)......................................................................... ......................... 35 
 4.4.4  Thymic Irradiation (Day -1)……………………………………………………………………………………………… ……….  36 
 
4.4.5 Tacrolimus Administration and Dosing (Day –1)........................................................................... 36 
 
4.4.6 Prednisone (Days 4 –20, 22 –42) and Methylprednisolone (Days 22 –42) ..................................... 3 7 
 4.4.7 ATG  Administration in the event of Engraftment Syndrome…… ….......................... …………… ……….3 7 
 4.4.8 Immunosuppression Withdrawal ................................................................................................. 3 7 
 4.5 TRANSPLANT PROCEDURES ..........................................................................................................39 
 
4.5.1  Bone Marrow Transplant (Day 0) ................................................................................................. 39 
 
4.5.2  Renal Transplant (Day 0) .............................................................................................................. 3 9 
 4.6 PROPHYLAXIS AGAINST AND TREATMENT OF INFECTION.............................................................40 
 4.6.1  Pneumocystis and Urinary Tract Infections.................................................................................. 40  
 4.6.2  Fungal and Yeast Infections  ......................................................................................................... 40 
 
4.6.3  CMV Infection ............................................................................................................................. . 40 
 
4.6.4  Herpes Infection ........................................................................................................................... 42 
 4.7 ASSESSMENT OF ALLOGRAFT DYSFUNCTION AND TREATMENT OF RENAL REJECTION.......... ......4 2 
 4.7.1  D efinition of Allograft Dysfunction and Indication for Biopsy...................................................... 42 
 4.7.2  Diagnosis, Grading and Monitoring of Rejection.......................................................................... 42 
 
4.7.3  Treatment of Rejection ................................................................................................................ 4 2 
 
4.8 PROHIBITED MEDICATIONS...........................................................................................................4 3 
 9 
 
 
4.9 DRUG ACCOUNTABILITY ..............................................................................................................4 3 
 5. STUDY PROCEDURES.............................................................................. ....................................... 4 3 
 
5.1 GENERAL ASSESSMENTS............................................................................................................ ...43 
 
5.2 LABORATORY ASSESSMENTS..................................................................................................... ....44 
 5.3 RENAL BIOPSY ...................................................................................................................... .........4 5 
 5.3.1 Renal Core Biopsy ...................................................................................................................... ....45 
 5.3.2 Intraoperative Wedge Biopsy  ...................................................................................................... 4 5 
 
5.3.3 For-Cause Kidney Biopsy  .............................................................................................................. 4 5 
 
6 ADVERSE EVENTS.......................................................................................................................... 45 
 6.1 OVERVIEW .................................................................................................... .................................4 5 
 6.2 DEFINITIONS .................................................................................................................................45 
 6.2.1 Adverse Event .............................................................................................................................. 45 
 
6.2.2 Serious Adverse Event ................................................................................................................. 46 
 
6.2.3 Unexpected Adverse Event .......................................................................................................... 46 
 6.3 COLLECT ING ADVERSE EVENTS......................................................................................................46 
 6.4 GRADING, ATTRIBUTION AND REPORTING OF ADVERSE EVENTS ................................................47 
 6.4.1 Grading Criteria. ............................................................................................................................ 47 
 
6.4.2 Attribution Definitions ................................................................................................. ................ 48 
 
6.4.3 Adverse Event  Reporting Requirements  ......................................................................................48 
 7 STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN ......................... .................................... 48 
 7.1 ANALYSIS SAMPLES.......................................................................................................................48 
 8 QUALITY CONTROL AND QUALITY ASSURANCE.......................................................................... 48 
 
9 ETHICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL PRACTICE..................... 49 
 
9.1 STATEMENT OF COMPLIANCE ....................................................................................................48 
 10 
 
 
9.2 INFORMED CONSENT...................................................................................................................49 
 9.3 PRIVACY AND CONFIDENTIALITY ...................................................................................................4 9 
 
REFERENCES .............................................................................................................................................. 50 
 
 List of Appendices  
 Appendix 1. Diagnosis and Classification of Selected Opportunistic Infec tions ........................................ 53 
 Appendix 2. Current Banff Classification of Renal Allograft Pathology (Banff 2005) ....………………………….54  
 Appendix 3. Staging and Grading of Graft -Versus -Host Disease ........................ ................................... .... 56 
 Appendix 4. Donor Evaluations ..................................................................................................................57  Appendix 5 MEDI -507 Dose Preparation Instructions ...................................................................... ........ 59 
 Appendix 6. Long Term Patient Follow -Up…………………………………………………………………………………….……… 60 
 Appendix 7: Schedule of Events for Safety Follow -up……………………………………………………………………………. 70 
  
List of Tables  
 
Table 1.  Patient summaries for all CKBMT Trials ………………………………………………………………………….……….. 19 
 Table 2. Dosing nomogram for treatment of CMV infection .................................................................... 41 
 Table 3. Attribution of adverse events ........................................................................................ .............. 48 
  List of Figures  
 Figure 1.   Long Term Results of Kidney Transplantation ............................................................................ 13 
 Figure 2. Conditioning R egimen  ............................................................................................................ .... 14 
 Figure 3.   Conditioning Regimens for Previous Clinical Trials……………………………………… ……….…………… .... 17 
 Figure 4.   Clinical Course…………………………… …………………………………………………………………………………….. …..2 0 
  
 
  
 11 
 
  1. B ACKGROUND  
 
 
1.1 SUMMARY    
Risk of long -term immunosuppression  
         Since the first successful human kidney transplantation by Murray et al. in 1956 1, 
numerous immunosuppressive regimens have been developed for clinical application.  As these 
more efficacious imm unosuppressive drug combinations have successfully prevented or treated 
acute allograft rejection, short -term survival of organ transplants has significantly improved, 
resulting in solid organ transplantation becoming the therapy of choice for many end -stage 
organ diseases 2,3.  
          However, chronic use of immunosuppressive drugs results in significantly increased risks of cardiovascular dis ease 
4-6, infection 7-9 and malignancies 10-13. Immunosuppressive 
medications also  cause various side effects, such as nephrotoxicity, de novo diabetes 14-16, 
dyslipidemia 17-20 and neurotoxicity 21,22. Cardiovascular disease has become the most common 
cause of mortality, accounting for 30 -48% of the deaths after kidney transplantation 10. 
Infection is also a common complication and remains the second most common cause of mortality after transplantation 
7-9. The risk of many common cancers has been observed to be 
higher  in chronically immunosuppressed transplant patients. Such risk is particularly high in 
non-melanoma skin cancer and melanoma/leukemia, which are 30 and 3 -fold higher than that 
in the general population, respectively11,23. Some studies report that the overall incidence of 
cancer after kidney transplantation is as high as 40% after 20 years of immunosuppressive therapy, in contrast to a 6% cumulative risk for cancer in an age - matched, non- transplanted 
control population 
13,24. Because of these morbidities, death with a functioning graft accounts 
for 16% of graft losses over the first 10 years after kidney transplantation 25. Chronic 
nephrotoxicity from calcineurin inhibitor (CNI) treatment is also a serious side effect Unfortunately, despite these toxicities that accompany the potent immunomodulatory effects of current therapeutic protocols, development of chronic rejection is not consistently prevented.  Approximately 15 -30% (dependent upon the assay utilized) of renal transplant 
recipients receiving maintenance immunosuppression even tually develop anti- HLA antibodies 
27. Chronic rejection, often in association with de novo alloantibody detection, accounts for 
about 20% of graft losses by 10 years after kidney transplantation 25. In summary, the net effect 
of these limitations of currently available chronic immunosuppression protocols is an 
inexorable loss of previously functioning transplanted kidneys at an annual rate of about 5 -7% 
28 and minimal improvement of renal graft half life in the last 10 years 2,3,29 (Fig. 1)  
 
    
 12 
 
Figure 1.  Long Term Results of Kidney Transplantation  
Rationale of tolerance induction  
           Induction of tolerance has been considered one strategy to improve the long -term results 
of organ transplantation. Operational tolerance (defined as the absence of a destructive 
immune response to a transplanted tissue without ongoing immunosuppression) is very rare in kidney transplant recipients. These observations have emphasized that additional conditioning or treatment is required for consistent induction of tolerance across major histocompatibility complex (MHC) barriers. In order to justify clinical application, development of such additional conditioning / treatment regimens must utilize approaches with short and long -term risks that 
do not outweigh the benefits over current standard of care.  Presumably, if tolerance could be induced consistently, chronic rejection would be eliminated and the risks of cardiovascular disease, infection, malignancy and other drug -related complications should be considerably 
minimized.  These advantages must be balanced against the potentially increased risks of infection and treatment -related morbidities in the early post -transplant period, which may be 
higher after administration of the conditioning regimens required for tolerance induction.  
Tolerance induction via the mixed chimerism approach  
 
          Evidence  that tolerance  of kidneys can  be induced via bone marrow bone marrow 
transplantation  in hum ans is illustrated  by the  fact that recipients  of successful allogeneic  
bone  marrow  transplants  who subsequently suffer  end-stage  renal  disease  have  undergone  
kidney transplantation from  the same donor  without the need  for immunosuppressive  
therapy. However, myeloablative conditioning for full allogeneic  bone  marrow  
transplantation,  specifically  for the induction  of tolerance  of the kidney  allograft,  is neither  
necessary  nor desirable.  Non myeloablative  
conditioning  regimens have  been  shown  to result  
 13 
 
in mixed chimerism and donor -specific  immunologic  tolerance  in a num ber of rodent  model  
systems, 32,33 in miniature  swine, 34 and in fully  mismatched  cynomolgus monke ys. 35-37   Our 
group  has reported  the successfu l induction  of tolerance in  patients  with  advanced  multiple  
myeloma and renal failure  through simultaneous  bone  marrow  and renal transplantation from 
HLA matched donors  (ITN study  NKD01) .38,39   More  recentl y, we have  reported  tolerance  
induction in  patients  with  end-stage  renal disease  (ESRD) w ithout my eloma who  received  
haploidentical  kidney and  bone  marrow  transplants  (ITN study  NKD03)40.  The originally 
studied protocol was revised (ITN036) to add rituximab and a short course of steroids and 
postoperative cyclosporine was replaced with tacrolimus to address the limitations of  
“engraftment syndrome” and development of donor specific antibody (DSA) observed in 
protocol (NKD03).  Although recipients treated with ITN036 did not develop DSA or humoral 
rejection, “engraftment syndrome” continued to be observed. The goal of this study is to develop a nonmyeloablative regimen that can induce comparable levels of transient mixed chimerism without “engraftment syndrome”.  The  proposed conditioning  regimen is depicted 
in Figure  2. Comparison with Figure 3 emphasizes that the only significant change from our 
most recently used conditioning is the substitution of TBI for cyclophosphamide on days - 5 
and -4. Our conditioning regimen in NHPs has always utilized TBI ( 100-150 cGy on days -5 and 
-4), with which the majority of recipients develop mixed chimerism and survive long -term 
without evidence of engraftment syndrome or allograft rejection Nevertheless, cyclophosphamide had been selected for the initial clinical trials because, at that time, there was more  extensive experience wit h this approach in human BM recipients. If the creatinine 
begins to rise  or the  level of donor chimerism falls by > 50%  during the 2
nd post -transplant 
week, Prograf will be discontinued and ATG will be administered ( up to 5 doses over 10 days ). 
Prograf administration will be resumed after ATG is discontinued.  This addresses our 
observation of apparent synergistic CNI nephrotoxicity with that of engraftment syndrome (See below: Clinical studies ). 
 
Figure  2. Conditioning  regimen  
 
 
 1.5 
 14 
 
1.2 PRECLINICA L AND CLINICAL  STUDIES  
 
1.2. 1 Preclinical Studies    
We have  previously  demonstrated that the establish ment of allogeneic  mixed chimerism  (i.e.,  
survival of  both  host  and donor  lymphohe matopoietic  elements)  with  a nonmyeloablative  
conditioning regi men across  MHC barriers  can successfully  achieve  transplantation  tolerance  
while  otherwise maintaining  full immunoco mpetence in mice, 41,42  in miniature  swine, 34 and 
in fully  mismatched c ynomolgus m onke ys. 35-37   Studies  of the mechanism of tolerance  
induced by mixed chimerism  have been  carried  out most extensively  in mice, and have  
demonstrated  that tolerance  is induced  centrally through  a deletional  mechanis m, as 
established  by analy ses of T-cell receptor  utilization . 43  Despite the  more extensive  
mechanistic  studies  we have  carried  out in mice and miniature  swine,  we shall confine  the 
preclinical  data  summarized  here  to our studies  in cynomolgus m onke ys, as these  animals are  
most relevant  to the present  protocol.   
The initially successful non myelo ablative  conditioning  regimen develop ed for induction of 
mixed chimerism  and renal allograft  tolerance  in MHC fully  mismatched cy nomolgus 
monke ys35 consisted  of total  body irradiation  (TBI),  thym ic irradiation  (TI) and antith ymocyte 
globulin.  Splenecto my, bone marrow  transplantation,  and renal  transplantat ion were  
perfor med on day 0 and cyclosporine  was administered  on days 0– 28. Of 13 recipient  
monke ys undergoing  this conditioning, 11  developed  mixed chimerism and 10 survi ved long -
term  without  allograft  rejection . 35,36,44    In these long -term  survivors,  alloantibody  and 
chronic  vasc ulopathy  were  detected in only  1 m onkey  that had not developed  clear 
macrochi merism. Further more, all long -term  survivors  showed  donor -specific 
unresponsiveness  in mixed lymphoc yte response  (MLR) assa ys35  The longest  surviving  
tolerant monkey  was observed for  more than  13 years  post  transplant,  with  a serum  
creatinine  of 1.2 mg/dL and a BUN of 19 mg/dL; a renal biopsy  at 10 years  post  transplant  
showed  no diagnostic  abnor malities, indicating  that this protocol  appears  to not only  avoid 
acute  rejection  but to prevent  chronic  rejection, which  is the major cause  for loss of long -
te
rm renal  allografts.  To our knowledge,  of all published protocols  leading  to long -term  
survival of renal allografts  in nonhu man prim ates,  this mixed chi merism  approach  is the only  
one which  avoids  chronic  rejection.  Several m odificatio ns of our regi men utilizing  either  
reduced doses  of TBI, no TI, or no cyclosporine  failed  to induce  chimerism, and  all allografts  
were  rejected;  elim ination  of the splenecto my did not prevent  the develop ment of 
chimerism  in all animals but resulted  in graft loss.35 
On the basis  of furthe r murine studies  in our research  center, 43,45 additional  studies  in 7 
cynomolgus monke ys evaluated  several m odifications  to the original protocol.  The addition  of 
costi mulatory blockade  with  anti-CD40L  antibody  improved  the reliability  of engraft ment and 
tolerance  induction without  the require ment for splenecto my 37. Five monke ys received  anti-
CD40L  added to the original regi men, including  cyclosporine  but without  splenecto my, all 
developed  chimerism, and none developed  anti-donor  antibodies.  Of these  five monke ys, one 
died  due to a urethral stone  on day 204, without  evidence  of allograft  rejection,  and one 
developed  hemoly tic uremic syndro me of unexplained  origin;  the other  three  monke ys 
remained  stable  without  evidence  of rejection for more than 8 years.  These  data  suggested  
that i mprove ment in T-cell depletion,  with anti-CD40L  as used  in this study, could  improve  the 
reliability  of engraft ment and toleran ce induction without  the need  for splenecto my.  
 15 
 
Most importantly, our pre -clinical studies indicated that induction of transient mixed 
chimerism is sufficient to induce tolerance of MHC fully mismatched renal allograft. Because 
chimerism has always been transient, no GVHD has been observed in these monkeys. The 
recipients treated with TBI -based conditioning regimen lost their chimerism more slowly than 
humans treated with cyclophosphamide -based conditioning regimen, no “engraftment 
syndrome” or acute kidney  injury have been observed in our monkeys.  
 
 
1.2. 2 Clinical Studies:  Prior Studies  
 
Introduction:  
          Since the seminal work reported by Billingham, Brent and Medawar on neonatal tolerance in 1956, numerous tolerance induction strategies have been identified in rodents. However, only a very limited number of these have been successfully translated to large animals and even fewer to primates. Among the few protocols that have been applied in humans, induction of donor chimerism, either transient or permanent, currently appears to be the most promising strategy to achieve renal allograft tolerance. Initial results of clinical trials for tolerance induction in three centers have so far been reported.  Using TLI and DBMT, the Stanford group reported succ essful induction of stable chimerism and renal allograft tolerance but only in HLA 
identical kidney transplant recipients.
46,47  More recently, Leventhal et al. at Northwestern have 
reported use of an intensive conditioning regimen and donor hematopoietic stem cells for 
induction of tolerance in HLA -mismatched kidney transplant recipients 48.  Although the follow -
up is still brief, persistent donor chimerism without GVHD has been reported, allowing weaning 
from all maintenance immunosuppression by 1 year in approximately half of their patients.   
         At Massachusetts General Hospital, based on decades -long basic studies in animal models 
32,35,37,49, we have applied combined kidney and donor bone marrow transplantation (CKBMT) 
for induction of allograft tolerance in both HLA matched and mismatched kidney transplant recipients 
38,39,50. The early results of the initial five mismatched patients who underwent 
CKBMT have been reported 40. We subsequently extended this approach with a revised regimen 
to five additional patients. We have submitted for publication our observations  in this later 
cohort as well as the longer- term follow -up (up to 10 years) of the previous recipients of HLA 
mismatched CKBMT (attached as Appendix 6 and briefly summarized here).  
 The three preparative conditioning regimens are depicted in Figure 3.  The  initial (NKD03) 
protocol was modified after treatment of the third subject who developed irreversible antibody 
mediated rejection, to include 1) administration of Rituximab, 375 mg/m²/dose on days - 7 and -
2; and 2) administration of prednisone, 2 mg/kg/d starting on the day of transplantation and 
then tapering over the next 10 post- transplant days (modified NKD03). Since subjects treated 
with this modified NKD03 still developed donor specific antibodies (DSA) after discontinuation 
of immunosuppression, the  regimen was further modified (ITN036) to add two more doses of 
Rituximab (375 mg/m²/dose  on post -transplant days 5 and 12, more prolonged administration 
of prednisone until day 20, and tacrolimus in place of CyA for the 5 most recently treated subjects. A total of 10 subjects, age 22 -46, 6 males and 4 females, were enrolled into these 
studies (Table 2).   
 16 
 
Donors were all HLA one haplotype mismatched parents or siblings. The first three subjects 
received the NKD03 regimen, the next two subjects received the  revised NKD03 regimen. The 
last five subjects received the ITN036 conditioning. All patients developed transient multilineage mixed chimerism which became undetectable by 2 -3 weeks post -CKBMT 
40,51. All 
subjects except for Subject #1 developed cytokine syndrome -like manifestations 40,52.  This 
syndrome has been temporally associated with the loss of peripheral chimerism as well as of the return of host -derived elements. The most concerning manifestation of this syndrome is 
acute kidney injury (AKI), which was observed after day 10 in all patients except for Subject #1. 
The biopsies taken during AKI showed severe endothelial injury with CD8
+ T cell infiltration, as 
reported in detail52. The peak of serum creatinine levels ranged from 3.5 to 15.4 during days 10 -
20. Among nine subjects who developed AKI, three recovered without additional treatment,  
two with Thymoglobulin and plasma exchange, one with Thymoglobulin alone and one with 
steroid pulse. Two kidney allografts failed to recover despite treatments due to associated humoral rejection and thrombotic micro -angiopathy.  
 
 
Clinical courses of all subjects are depicted in Figure 4.  
 
Subject #1  was a 22  y.o. female who has continued to be well with normal kidney allograft 
function without ongoing immunosuppressive therapy for more than 10 years. All four protocol 
Figure. 3 Conditioning Regimens for Previous Clinical Trials  
 17 
 
biopsies performed up to 8 years af ter CKBMT showed no evidence of rejection in light and 
electron microscopy. No DSA has been detected.   
Subject #2  was a 22 y.o. man in whom all immunosuppressive medications were tapered off by day 422. 
He remained stable until year 7 following immunosuppression withdrawal. At that point he was first 
noted to have increased urinary protein. Allograft biopsy revealed no rejection but recurrence of his 
original disease, MPGN type 1. Mycophenolate mofetil (MMF) monotherapy for recurrent MPGN was initiated aft er the 8
th year. He is currently stable without further increment of proteinuria.  
Subject # 3  was known to have positive PRA (50%) but ADA was not detectable by ELISA 
preoperatively. This subject developed severe irreversible acute humoral rejection on day 10.   
The protocol was subsequently modified with more strict inclusion criteria (PRA pretransplant 
detection against any specificity became a contraindication) plus the addition of two doses of pre-transplant rituximab and post- transplant  prednisone up  to day 10 (modified NKD03).    
Subject #4  was a 25 y.o. man whose Immunosuppression was tapered and completely discon -
tinued on day 244. This subject developed anti - HLA class II DSA, soon after complete 
discontinuation of immunosuppression. His five -year  protocol biopsy revealed basement 
membrane duplication by electron microscopy with minimal interstitial fibrosis and no evidence of cellular or vascular rejection. Although his kidney allograft function has continued to be stable with serum creatinine of 1.6 -1.9 mg/dl, he has recently developed mild proteinuria at 7 
years post -transplant, and treatment with IVIG and MMF therapy have been recommended.  
Subject #5  was a 46 y.o. male in whom immunosuppression was tapered and discontinued 
completely on day 272 .  He remained stable for 5 years with no evidence of rejection or C4d 
deposition in either light or electron microscopy.  However, after suffering severe episodes of gout, his renal function became unstable with detection of DSA by ELISA at 6 years. Since  DSA 
became positive with newly appeared C4d deposition in the biopsy, he received a short course of high dose IVIG (2g/kg) followed by rituximab. His in vitro  CML and MLR assays have 
continued to show complete absence of anti -donor T cell responses. After  these treatments, his 
renal function stablized with no evidence of chronic humoral rejection and C4d staining returned to negative in the subsequent biopsy. He is currently doing well without maintenance immunosuppression.  
Subject # 6  developed AKI after day 10 but recovered without additional treatment. His 
immunosuppression was slowly tapered and completely discontinued at 8 months after CKBMT. He is currently at 3.5 years after transplantation and has been well, without immunosuppression and with a serum creatinine level of 1.5 mg/dl. Biopsy showed no evidence of rejection by either light or electron microscopy.  
Subject # 7  had her immunosuppression tapered and completely stopped at 8 months. She is 
currently at 3 years and 4 months after CKBMT with normal kidney function (serum creatinine 0.8 mg/dl) with no evidence of rejection or C4d staining in the 2 year protocol biopsy  
Subject # 8  developed AKI after day 10. The renal allograft biopsy on day 11 showed no 
rejection but endothelial injury. Another b iopsy, performed on day 22 revealed intra- renal 
thrombotic microangiopathy, possibly due to tacrolimus toxicity. Tacrolimus was discontinued and three doses of anti -thymocyte globulin were administered with MMF. Despite these 
treatments, her kidney functio n did not recover and she was eventually returned to CAPD at 7 
months after transplantation.  
 18 
 
Subject #9  also developed transient AKI after day 10 and recovered without additional 
treatment. Her immunosuppression was discontinued at 8 months after transplantation. She is 
currently well at 3 years after CKBMT with normal kidney function (serum creatinine 1.0 mg/dl). The protocol biopsy at 2 years showed no evidence of rejection. No DSA has been detectable.  
Subject #10  developed AKI two weeks after CKBMT.  H is kidney function gradually returned to 
normal by 2 months after transplantation and a 6 -month protocol biopsy did not show 
rejection. His immunosuppression was completely discontinued at 8 months. At 9 months, he developed acute pyelonephritis of the kidney allograft with moderately elevated serum 
creatinine (2.2 from 1.6 mg/dl). This was treated with antibiotics and the kidney function 
recovered to base line levels. However, 3 weeks after the resolution of his UTI, he developed severe acute cellular reje ction (BANFF 2B) with no C4d staining.  DSA has never been detectable 
by either ELISA or LUMINEX. He was treated with steroid pulses and anti -thymocyte globulin, 
following which his renal function improved but never fully recovered.  Although he remains well, his compromised kidney function suggests that gradual progression to ESRD is likely.  
 
Table  1. Patient summaries  for all CKBMT Trials  
 
   
 
            
  
          
B cell depletion : Recovery of CD3-CD19+ cells in two subjects (Subjects #1 and #2) trea ted with 
the original NKD03 regimen was observed by days 50 and 100, respectively.  With two doses of pre-transplant rituximab (modified NKD03), depletion of CD3
-CD19+ cells was extended to day 
150 (Subjects #4 and #5) but complete loss of CD3-CD19+ cells from the peripheral blood was 
not observed. In contrast, peripheral blood CD3-CD19+ cells were essentially undetectable for 6 
months in all five subjects treated with 4 doses of peritransplant rituximab (ITN036). Of note although DSA has been detected at least transiently in 4 of 5 NKD03, no DSA has been detectable in all ITN036 subjects.  
  
 19 
 
 
              
Despite the encouraging results of successful long -term tolerance induction in our initial clinical 
trials, the major obstacle to more wide -spread appli cation of this approach is the “engraftment 
syndrome”.  AKI is a major manifestation of engraftment syndrome and has been observed at approximately day 10 in all subjects except for Subject #1. Subject#1 had been treated with immunosuppression for 10 years  after her first transplantation (at age 12) before receiving 
CKBMT (at age 22), which may be the reason she was exempted from the engraftment syndrome.  This syndrome has been described previously following both autologous and allogeneic bone marrow trans plantation, which has been associated with the recovery of either 
host or donor type  hematopoietic elements 
26.  We note that the AKI of engraftment syndrome 
has never been observed in our MHC -mismatched monkey model, in which chimerism is also 
lost, but at a more gradual pace, usually over 2 -3 months 9,10,27.  Our current interpretation of 
these findings is that the pre -transplant cyclophosphamide -based regimen chosen for the 
clinical trials 14, in contrast to the non- myeloablative total body irradiation used in the monkey 
preparative regimen 9,10,27,28, may be inadequately suppressive, allowing rapid homeostatic 
recovery of host memory T cells resulting in rapid rejection of the donor hematopoietic graft.  Further supporting this hypothesis is the observation that AKI has also never been observed in our HLA -matched CKBMT recipients, in whom chimerism as in the NHP recipients typically 
disappears more slowly, over a period of 2 -3 month s 
12,13.   Figure 4  Clinical Course  
 20 
 
The proposed pilot protocol is planned to address the “engraftment syndrome” related AKI, 
which currently remains the only major obstacle to wider clinical application of this approach.  
 
1.3 RISKS TO PARTICIPANTS  
 1.3.1  MEDI -507  
 The following information for MEDI -507 was taken from the  current investigator’s brochure.  
 
The safety profile of MEDI -507 is based on over 600 patients with psoriasis, 70 patients with GVHD or 
renal transplantation, and 29 patients with lymphoproliferative disorders. The most serious adverse 
events in patients treated with MEDI -507 are:  
• Infusion -related/cytokine- release syndrome  
• Infections  
• Secondary cancers  
 
The following adverse events have been observed in patients treated with MEDI -507, and may be 
potentially related to MEDI -507 therapy:  
 
Infusion -related/cytokine- release syn drome:  Infusion -related reactions such as chills, pyrexia, and 
fatigue have been commonly seen in patients with cancer, GVHD and renal transplantation, and psoriasis. These events have been mild to moderate in severity, transient in nature, and have not recurred with rechallenge. Other associated events included nausea, vomiting, and hypotension.  
 
Infections:  T-cell antibodies may be immunosuppressive. Prolonged immunosuppression may increase 
the risk of infection, including opportunistic infections. Infections were common in both the cancer and GVHD studies. Infections occurred in 3 (16%) of 19 patients in MI -CP099, with 5 patients (26%) having 
positive CMV antigen. Three patients discontinued treatment after testing positive for CMV (protocol-specified reason for discontinuation of MEDI -507). In MI -CP107, there were two infection -associated 
SAEs (staphylococcal bacteremia and RSV infection) that occurred in 2 (20%) of 10 patients; both events were judged by the investigator as not being related to MEDI -507.  In MI -CP042, infections occurred in 
16 of 17 patients and were a primary cause of death in 6 patients. The most common infectious agents were staphylococci followed by CMV. Three patients developed infections with Aspergillus or other mycelial fungi. A single patient experienced cryptosporidiosis involving the lung and colon. In MI -CP046, 
infections were common in both MEDI -507 (19 [90%]) and placebo (12 [92%]) patients and the most 
common site of infection was blood. The most common isolates were the same  among MEDI -507 and 
placebo patients, and included staphylococcus species, CMV and enterococcus. The incidence of fungal infections (primarily Candida) was higher in the pooled placebo group (7/13, 54%) than among MEDI -
507 patients (4/21, 19%). In MI -CP049 , infections were seen in 3 of 10 patients (30%).  
 
Secondary cancers:  Prolonged and sustained immunosuppression may result in an increased risk of 
developing certain types of cancer.  
 EBV- associated LPD, PTLD, and lymphoma have occurred in clinical trials of MEDI -507. In the two cancer 
trials of MEDI- 507 (MI -CP099 and MI -CP107), EBV -LPD has been reported in five patients including two 
patients with LGL and one patient each with CTCL, peripheral T -cell lymphoma (PTCL), and ATL. Most of 
these patients (4 of 5 ) who developed EBV -LPD received ≥ 3.4 mg/kg/dose MEDI -507, and all cases were 
 21 
 
j u d g e d as h a vi n g eit h er a p ossi bl e r el ati o ns hi p ( 2 of 5 p ati e nts) or pr o b a bl e r el ati o ns hi p ( 3 of 5 p ati e nts) 
t o M E DI -5 0 7. O n e p ati e nt wit h L GL d ev el o p e d a s ec o n d ar y l e u k e mi a ( M 4  ty p e l e u k e mi a) 1 y e ar aft er 
c o m pl eti n g M E DI -5 0 7 t h er a py. T h e e v e nt w as gr a d e 5 (f at al) a n d j u d g e d as r e m ot el y r el at e d t o M E DI -
5 0 7 tr e at m e nt.  
 
I n t h e G V H D st u di es of M E DI -5 0 7 (st u di es MI -C P 0 4 2 a n d MI -C P 0 4 9 i n T a bl e 3), E B V -L P D a n d P TL D h av e 
b e e n r e p ort e d i n o n e p ati e nt e ac h, a n d E B V -l y m p h o m a h as b e e n r e p ort e d i n t w o p ati e nts. A c as e of 
A ML r el a ps e h as als o b e e n r e p ort e d.  
 
I n t h e st u dy of r e n al tr a ns pl a nt p ati e nts, o n e p ati e nt ex p eri e nc e d a b as al c ell c arci n o m a of t h e ski n o n 
a n ar e a of acti nic ex p os ur e r e p o rt e d d uri n g l o n g -t er m f oll o w -u p. T w o p ati e nts i n t h e ps ori asis st u di es 
h a d s ec o n d ary m ali g n a nci es (s q u a m o us c ell c arci n o m a of t h e s ki n a n d M D S) f oll o wi n g tr e at m e nt wit h 
M E DI -5 0 7. B ot h p ati e nts h a d a pri or hist ory of t h es e r es p ectiv e c o n diti o ns, a n d w er e e nt er e d i nt o a 
M E DI -5 0 7 ps ori asis st u dy i n vi ol ati o n of pr ot oc ol e ntry crit eri a t h at excl u d e d p ati e nts wit h a hist ory of 
c a nc er ( alt h o u g h i n t h e l att er c as e, t h e c o n diti o n w as n ot discl os e d at st u dy e nr oll m e nt).  
 
T hr e e c as es of P TL D h a v e b e e n r e p ort e d i n i nv esti g at or -i niti at e d a n d c o m p assi o n at e us e st u di es of 
M E DI -5 0 7.  
 
1. 3. 2  Rit u xi m a b  ( Rit u x a n ®)  
 
T h e f oll o wi n g i nf or m ati o n f or rit uxi m a b w as t a k e n fr o m t h e Rit ux a n p ac k a g e i ns ert.  
 
I n dic ati o ns f or us e:  Rit ux a n ( Bi o g e n I d ec I nc. a n d G e n e nt ec h U S A, I nc., S o ut h S a n Fr a ncisc o, C A) is a 
C D 2 0 -dir ect e d cyt ol ytic a nti b o dy i n dic at e d f or t h e tr e at m e nt of t h e f oll o wi n g:  
 
• N o n -H o d g ki n’s ly m p h o m a ( N HL).  
• R h e u m at oi d art hritis ( R A) i n c o m bi n ati o n wit h m et h otr ex at e i n a d ult p ati e nts wit h m o d er at el y - 
t o s e v er ely -activ e R A w h o h a v e i n a d e q u at e r es p o ns e t o o n e or m or e T N F a nt a g o nist t h er a pi es.  
 
C o m m o n a dv ers e ev e nts:  
 
• N HL ( 2 5 %): i nf usi o n r e acti o ns, f ev er, l y m p h o p e ni a, c hills, i nf ecti o n a n d ast h e ni a.  
• R A ( 5 %): hy p ert e nsi o n, n a us e a, u p p er r es pir at or y tr act i nf ecti o n, art hr al gi a, pr uri t us, a n d 
pyr exi a. Ot h er i m p ort a nt a dv ers e r e acti o ns i ncl u d e i nf usi o n r e acti o ns, s eri o us i nf ecti o ns, a n d 
c ar di o v asc ul ar ev e nts.  
 
S eri o us a dv ers e ev e nts:  
 
T h e f oll o wi n g s eri o us a dv ers e ev e nts h a v e b e e n ass oci at e d wit h us e of Rit ux a n:  
 
• T u m or l ysis sy n dr o m e  
• Se v er e m uc oc ut a n e o us r e acti o ns  
• P ML  
• H e p atitis B r e acti v ati o n wit h f ul mi n a nt h e p atitis  
• C ar di ac arr hyt h mi as a n d a n gi n a  
• B o w el o bstr ucti o n a n d p erf or ati o n  
 2 2  
 
 
For additional information, please refer to the package insert at the following web site:  
 
http://www.gene.com/gene/products/information/pdf/rituxan -prescribing.pdf  
 
Note: Most of the serious adverse events were related to tumor lysis in the treatment of cancer and are 
therefore not thought to be relevant to the current protocol.  
 1.3.3  Low Dose Total Body Irradiation   
 
Low dose TBI  may cause  bone  marrow  suppression,  immune suppression,  nausea,  vomiting. There  is a 
possibility  that TBI with  or without  other anti -lymphocy te therapy  may lead  to a malignancy  months  or 
years  following  the transplant.  Epidemiologic studies have established that low dose TBI ( 250 300 
cGy) increases the life -time risk of malignancy by a factor of 1.2 over that observed in individuals 
without pri or exposure to irradiation (33). In contrast, as described above, long- term 
immunosuppression is associated with a 2 -30 fold increased risk of cancer (13, 24) . Such data would 
appear to justify the use of low dose irradiation for tolerance induction.   
 
Because of the risk of genetic  damage,  all wo men of childbearing  years  will have  a pregnancy  test 
before  starting  the treat ment. Although rep roductive organs will be shielded, TBI m ay also result  in 
sterilit y, cause  genetic damage to future  offspring,  or interfere in  normal wound healing.  
 1.3.4  Thymic  Irradiation  
 Irradiation of the thymus gland may cause nausea, vomiting, mild skin irritation and inflammation of the esophagus (causing mild, temporary dysphagia). Occasionally, pericarditis or pneumonitis may occur. 
Hypothyroidism and secondary malignancies are additional potential risks.  
 
There is a risk of multi-organ failure, including cardiac, renal, pulmonary, CNS, and hepatic failure. This risk is increased in patients who have already had significant chemotherapy or radiation therapy or both. These risks may be life threatening and lead to fatal complications.  
 There is a possibility that the chemotherapy with or without radiation therapy may lead to a malignancy months or years following the transplant. Because of the risk of genetic damage, all women of childbearing years will have a pregnancy test before starting the treatment.  
 
1.3.5  Tacrolimus  
 
Side effects of tacrolimus include renal insufficiency, abnormal liver function studies, seizures, nausea, vomiting, confusion, hypomagnesemia, tremulousness, and increased risk of secondary malignancies. Co-administration with methylprednisolone will decrease hepatic metabolism and thus increase 
tacrolimus levels; convulsions have been reported with concomitant high doses of methylprednisolone.  
Additional information about tacrolimus can be found in the package insert at 
http://www.astellas.us/docs/prograf.pdf  
 1.3.6  Prednisone   
 
 23 
 
Side effects of corticosteroids include convulsions, headache, vertigo, mood swings, psychosis, 
congestive heart failure (CHF), hypertension, Cushing syndrome,  menstrual irregularities, hyperglycemia, 
GI irritation, peptic ulcer, weight gain. Dermatologic effects may include thin skin, petechiae, ecchymosis, facial erythema, poor wound healing, hirsutism, and urticaria. Muscle weakness, loss of muscle mass, and osteoporosis may also occur. Ophthalmologic complications may include increased 
intraocular pressure, glaucoma, exophthalmos, and cataracts. Other complications may include immunosuppression and increased susceptibility to infection.  
 For further informati on about prednisone, see the package insert at  
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16633  
  1.3.7 GVHD  
 Since induction of persistent chimerism is not expected wi th our nonmyeloablative regimen, the risk of 
GVHD is considered very low. No GVHD has been observed in 10 patients who received combined kidney and bone marrow transplantation from HLA -mismatched donors under a similar protocol (NKD03 and 
ITN 036; see sect ion 1.2.2).  
  The risk of GVHD increases depending on the severity of the conditioning regimen. In allogeneic bone marrow transplantation with meloablative conditioning, acute GVHD and/or chronic GVHD are common complications (30 -90% acute GVHD risk depend ing on the degree of HLA match and subject age group; 
30% –50% chronic GVHD risk with conventional transplants). In our series of patients  with neoplastic 
conditions receiving HLA -identical nonmyeloablative bone marrow transplants, the risk of GVHD in the 
absence of DLI has been approximately 30%, and with only a few exceptions, has been grade II GVHD 
confined to the skin. In recipients of a single DLI on day 35, the risk of acute GVHD has been 
approximately 40% (4 of 10 patients), and three of these have also been grade II GVHD of the skin, with or without the subsequent development of chronic GVHD. In 37 HLA -identical transplants using an ATG-
containing regimen, we observed a 30% incidence of grade II or more acute GVHD overall. As noted in section 1.2.2, no GVHD was observed in ten non-HLA- identical bone marrow transplant recipients after 
treatment with our MEDI -507-containing conditioning regimen. 
 1.3.8 Renal Graft Failure  
 
The 2010 Annual  Report  of the U.S. Scientific  Registry  of Transplant  Recipients  and the Organ 
Procure ment and Transplantation  Network  estimates  1, 5 and  10-year graft  survival rates  for renal 
allograft  recipients  of living  donor  allografts  as 97% , 80% and 60%,  respectivel y, based  on over  64,000 
transplants  perfor med between  1998 and 2010.  Thus,  the short -term outco mes for living  donor  renal  
graft recipients  using conventional  treat ment methods  are excellent,  but long- term results have not 
been satisfactory. Although 7/10 recipients who received previous regimens are doing well with the longest 
survival exceeding 10 years, the outco mes for the experi mental intervention  described  in this protocol  
are unknown.  
 
1.3.9   Infection  
 While it is recognized that the transient pancytopenia and temporary T -cell depletion induced by 
conditioning for BMT under this protocol could theoretically lead to an increased risk of infection post 
transplant, our experience to date (with over 200 primate renal allografts performed with a similar type 
 24 
 
of protocol, and with the 10 patients receiving a simultaneous kidney and marrow transplant at MGH) 
has been that infection is not a major problem. This probably reflects the high level of attentiveness to potential infectious complications among the surgical and BMT staff and the prophylactic antimicrobial treat ments that are used.  
 
 1.3.10   Bone Marrow Transplant -related Mortality  
 
There was no bone marrow transplant mortality in 10 patients treated with combined kidney and bone marrow transplantation. Additionally, no patient mortality has also been seen in 1 0 myeloma recipients 
who received CKBMT with similar conditioning regimen. {Spitzer, 1999 #42} {Spitzer, 2011 #3568}  
 1.3.11   Renal  Biopsies  
 A wedge biopsy is performed on the day of transplant. Complications for the wedge biopsy include hemorrhage, renal infarction, infection, retention cysts, urine fistula, and hydronephrosis. All 
subsequent biopsies are performed percutaneously under ultrasound guidance with an 18 -gauge 
needle.  The biopsy will be performed only in patients with platelet counts >50,0 00. The most frequent 
complication of temporary, self- limited bleeding occurs in approximately 2% of allograft recipients at 
the MGH.  
 
There has been no significant allograft dysfunction or loss of an allograft due to a biopsy in over 500 consecutive pati ents. The procedure is performed in the out -patient radiology suite, and the patient is 
monitored for stability in the transplant unit for approximately 8 hours prior to discharge on the evening of the biopsy. In the case of a rare but significant bleeding  event resulting from the renal biopsy, 
transfusion with packed red blood cells may or may not become medically necessary.  
 1.3.12   Leukapheresis   
 Leukapheresis will be performed on the recipient prior to initiating the conditioning regimen and these cells will be frozen. In the  unlikely  event that the recipient develops GvHD, we will give the 
leukapheresis product to the participant (intravenous infusion), to treat the GvHD. If the participant does not develop GvHD, the leukapheresis product will be used  for in vitro studies. Complications that 
may occur during leukapheresis include changes (increase or decrease) in blood pressure or pulse, bleeding, or hypocalcemia. Bleeding, fever, and  infection from leukapheresis can also occasionally occur. 
On rare oc casions, these complications may be life -threatening.  
 1.3.13   Engraftment  Syndrome  
 Engraftment  syndrome was observed in nine of the 10 patients in NKD03/ITN036. This syndrome, which 
is associated with the loss of chimerism and hematopoietic recovery of the recipient   (typically during 
the second week after bone marrow administration), is characterized by fever, fluid retention, and renal dysfunction., all of which respond to steroids and are reversible. Acute kidney injury (AKI) is a major manifestatio n of engraftment syndrome and has been observed at approximately day 10 in all subjects 
except for Subject #1.  This syndrome has been described previously following both autologous and allogeneic bone marrow transplantation, which has been associated with  the recovery of either host or 
donor type  hematopoietic elements 27.  We note that the AKI of engraftment syndrome has never been observed in our MHC -mismatched monkey model, in which chimerism is also lost, but at a more gradual 
pace, usually over 2 -3 months.9,10,28  Our current interpretation of these findings is that the pre-
 25 
 
transplant cyclophosphamide -based regimen chosen for the clinical trials,15  in contrast to the non -
myeloablative total body irradiation used in the monkey preparative regimen,9,10 ,28,29  may allow 
rapid homeostatic recovery of host memory T cells, which may be associated with significant effector 
function, as suggested by the observation of CD8 T cell activation immediately following conditioning 16 and rapid rejection of the donor  hematopoietic graft.  Further supporting this hypothesis is the 
observation that AKI has also never been observed in our HLA -matched CKBMT recipients, in whom 
chimerism as in the NHP recipients typically disappears more slowly, over a periods of 2 -3 month s.  In 
this pilot trial, we expect that AKI can be prevented by inducing more stable chimerism (but still expected to be transient chimerism) by substituting low dose TBI for cyclopshophamide.  
 1.3.14  ATG  (Thymoglobulin or ATGAM) 
 
The most common adverse events associated with ATG  are:  
• Moderate fever and chills  
• Leukopenia  
• Although rare, the most common severe events associated with ATG  are:  
o Allergic or anaphylactoid reactions  
o Serum sickness or serum sickness -like symptoms (fever, pruritus and rash asso ciated with 
arthralgia or myalgia)  
 
As with all immunosuppression, administration of ATG may be associated with an increased risk of 
infection and the development of malignancy (especially of the skin and lymphoid system). Thymoglobulin  (1.5 mg/kg/day × 3 –7 days ) the course can be extended in the case of delayed graft 
function) is standard induction immunosuppression for both cadaveric and living- donor renal 
transplants at many centers.   The carcinogenic effects and the effect of ATG on fertility have not been established. ATG is 
contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product excipients, or who have active acute or chronic infections that contraindicate any additional immunosuppression.  
 For additional information on the risks associated with ATG, refer to the package insert for Thymoglobulin® (Genzyme) at the following website: 
http://www.thymoglobulin.com/home/thymo_pdf_pi.pdf  
 For additional information on the risks associated with ATGAM, refer to the package insert for Atgam® 
(Pfizer) at the following website:  
http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/license
dproductsblas/fractionatedplasmaproducts/ucm199603.pdf   
 1.4 RISKS TO DONORS 
 1.4.1  Bone Marrow  Donation  
 Risks of bone marrow donation are related to either the administration of anesthesia or the operative 
procedure itself. Risks of anesthesia include, but are not limited to, postoperative nausea, vomiting, 
 26 
 
fatigue and rare life -threatening allergic reactions or h emodynamic instability. Most donors experience 
postoperative discomfort at the sites of bone marrow harvest. On average, the soreness and bruising 
last for approximately 2 –3 weeks post harvest. A small percentage of donors (less than 10%) experience 
prolon ged (weeks or months) pain or sciatic type pain, likely as the result of inflammation of the nerve 
roots from local bleeding or edema. Rare complications of bone marrow harvesting include local 
infection (including reports of osteomyelitis), pelvic fracture, phlegmon formation, pancreatitis, ileus, 
and fat embolism. Fatal complications following bone marrow harvesting are exceptionally rare and have been related to cardiopulmonary complications secondary to anesthesia or other catastrophic events, such as p ulmonary embolism.  
 1.4.2  Kidney Donation  
 Risks of kidney donation include the same anesthesia- related complications described above. The major 
postoperative morbidity associated with donor surgery includes pneumonia, wound infection, hematoma, phlebitis , pulmonary embolism, and urinary tract infection. The surgical complication rate 
for kidney donation is approximately 2%. The perioperative mortality for a living kidney donor is estimated to be 0.033%. Although uninephrectomy of living donors has been rarely associated with 
proteinuria and hypertension 6 –10 years following nephrectomy, careful study of long -term outcome in 
kidney donors (up to 23 years) and army personnel who lost kidneys due to trauma during World War II (45 years’ follow -up) did not sub stantiate an increased risk of hypertension or renal failure 
with uninephrectomy.  
 1.4.3  Combined BMT and Kidney Donation  
 The major risk to the donor for either nephrectomy or marrow procurement is that of general 
anesthesia. The simultaneous procurement  of kidney and bone marrow requires approximately an 
additional hour of anesthesia as compared to a nephrectomy alone.  
 
 1.5 RATIONALE FOR SELECTION OF CONDITIONING REGIMEN 
All previously treated human subjects except for Subject #1 developed cytokine synd rome -like 
manifestations 
40,52.  This syndrome has been temporally associated with the loss of peripheral 
chime rism as well as of the return of host -derived elements. The most concerning manifestation of this 
syndrome is acute kidney injury (AKI), which was observed after day 10 in all patients except for Subject #1. The biopsies taken during AKI showed severe endo thelial injury with CD8
+ T cell infiltration (Fig. 4), 
as reported previously in detail52. The peak of serum creatinine levels ranged from 3.5 to 15.4 during 
days 10 -20. Among nine subjects who developed AKI, three recovered without additional treatment, 
two with Thymoglobulin and plasma exchange, one with Thymoglobulin alone and one with steroid 
pulse. Two kidney allografts failed to recover despite treatments due to associated humoral rejection 
and thrombotic micro -angiopathy.   
This syndrome has been described previously following both autologous and allogeneic bone marrow 
transplantation, which has been associated with the recovery of either host or donor type  
hematopoietic elements 26.  We note that the AKI of engraftment syndrome has never been observed 
in our MHC -mismatched monkey model, in which chimerism is also lost, but at a more gradual pace, 
usually over 2 -3 months 9,10,27.  Our current interpretation of these findings is that the pre -transplant 
cyclophosphamide -based regimen chosen for the clinical trials 14, in contrast to the non -
myeloablative total body irradiation used in the monkey preparative regimen 9,10,27,28, may be 
 27 
 
inadequately suppressive, allowing rapid homeostatic recovery of host memory T cells resulting in 
rapid rejection of the donor hematopoietic graft.  Further supporting this hypothesis is the 
observation that AKI has also never been observed in our HLA -matched CKBMT recipients, in whom 
chimerism as in the NHP recipients typically disappears more slowly, over a periods of 2 -3 months 
12,13.  We therefore propose to replace cyclophosphamid e with low dose TBI in this clinical pilot study.  
 
 
2. STUDY DESIGN  
 2.1 DESCRIPTION 
 This is a single center, pilot study of 2 adults with end stage renal disease and no evidence of prior sensitization, and their donors.  
 Recipients will receive a conditioning regimen comprising rituximab, low dose whole body irradiation, MEDI -507 and thymic irradiation prior to combined renal and bone marrow transplant. A short 
postoperative course of steroids will be administered. Tacrolimus will be given for a defined p eriod and 
then tapered if specific criteria are met.  
 Prophylaxis will be provided for PCP, fungal/yeast infection, CMV, and perioperative infection.  
 The proportion of participants  without engraftment syndrome and  successfully withdrawn from 
immunosuppres sion will be assessed. Clinical outcomes will be compared with measurements of donor-
specific tolerance and other immune parameters.  
 Participants will be followed for a total of 5 years post CKBMT.  Assessment s will be performed for 
participant and graft survival, and long- term adverse events. Participants who fail to complete 
immunosuppression withdrawal will be followed for 104 weeks (24 months) from the time they cease further reduction in immunosuppression.  
  2.2 CONSENT FOR PARTICIPATION 
 
For individuals identified as potential candidates for the trial, a consent addressing all aspects of the 
trial, including the planned withdrawal of immunosuppression will be obtained before any screening procedures are performed for evaluation of a participant’s eligibility for the trial.  
 Informed consent will also be obtained from the donor and will be completed prior to performance of donor screening procedures .. 
 2.3 STUDY ENDPOINTS  
 2.3.1  Primary Endpoint  
 The primary endpoint of this study is successful inducti on of transient chimerism and renal allograft 
tolerance without “engraftment syndrome” or “acute kidney injury”.  
  
 28 
 
2.4 STOPPING RULES  
 
2.4.1  Ongoing Review  
 The Principal Investigator will review safety data. Enrollment of participants in the trial and w ithdrawal 
of immunosuppression in current trial participants will be suspended at any time if any of these reviews concludes that there are significant safety concerns.  
 2.4.2  Review of Specific Adverse  Events  
 If the following events occur at any time d uring the study, they will be reviewed by the DMC . Any 
occurrence of death , graft loss , GVHD greater than grade II or prolonged  neutropenia ( > 14 Days ) will 
result in suspension of enrollment pending DMC review.  
 
• Death of a participant.  
 
• Any malignancy (excluding basal cell carcinomas of the skin and CIS of the cervix) in two participants. 
 
• Renal graft loss or irreversible organ failure in any participant, as evidenced by a return to dialysis after 1 week post -transplant or a sustained serum creatinine >3 times that established at 
post -transplant baseline. See Section 4.7.1 for definition of baseline creatinine.   
 
• Humoral rejection in one participant.  
 
• Acute cellular rejection greater than or equal to grade IIB in two participants.  
 
• Acute GVHD greater than or equal to grade II in one participant.  
 
2.4.3  Data Monitoring Committee  
 The initial DMC meeting to review the study protocol will occur before the first patient receives CKBMT 
transplant. The review of participant data will occur 6 months after the first patient has received a transplant. Meetings will occur every 6 months thereafter. A DMC meeting  will also occur if any of the 
specific adverse events in section 2.4.2 occur in enrolled participants.  
 
 
2.5 ENROLLMENT, TIMING OF TRANSPLANT, AND LENGTH OF  FOLLOW - UP 
 
For this study, enrollment is defined as the day on which the informed consent is signed.   Participants who complete immunosuppression withdrawal will be followed for a  total of 5 years post 
CKBMT.  additional Assessments will be performed for participant and graft survival and for long -term 
adverse events  
 Participants who fail to complete immunosuppression withdrawal will be followed for 104 weeks (24 months) from the time they cease further reduction in immunosuppression.  
 29 
 
 
3. ELIGIBILITY  
 3.1 RECIPIENT INCLUSION CRITERIA  
 
Patients who meet all of the following criteria are eligible for enrollment as study participants:  
 
1.   Male or female 18 –60 years of age.  
 2.   Candidate for a living -donor renal allograft with a one haplotype identical  donor identified.  
 3.   First or second transplant with either a living donor or cadaveric transplant as the first transplant.  
 4.   Use of FDA -approved methods of contraception (those with less than a 3% failure rate) by all 
recipients from the time that study treatment begins until 104 weeks (24 months) after renal 
transplantation. (For further information on FDA -approved methods of contraception, see 
http://www.fda.gov/For Consumers/ByAudience/ForWomen/ucm118465.htm  
 5.   Ability to understand and provide informed consent.  
 6.   Serologic evidence of prior exposure to EBV.  
  3.2 RECIPIENT EXCLUSION CRITERIA  
 
Patients who meet any of these criteria are not eligible for enrollment as study participants:  
 
1.   ABO blood group -incompatible renal allograft.  
 2.   Evidence of anti -HLA antibody within 60 days prior to transplant as assessed by routine methodology 
(AGH and/or ELISA)  
 3.   Leukopenia (WBC less than 2,000/mm3) or thr ombocytopenia (platelet count <100,000/mm3).  
 4.   Seropositivity for HIV -1, hepatitis B core antigen, or hepatitis C virus (confirmed by hepatitis  
C virus RNA); or positivity for hepatitis B surface antigen.  
 5.   Cardiac ejection fraction ≤ 40% or clinic al evidence of cardiac insufficiency.  
 6.   Forced expiratory volume (FEV1) < 50% of predicted.  
 7.   Lactation or pregnancy.  
 8.   History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix.  
 
9.   Underlying renal disease etiology with a high risk of disease recurrence in the transplanted kidney 
(such as focal segmental glomerulosclerosis, type I or II membranoprolifertive glomerulonephritis).  
 
 30 
 
10. Prior dose -limiting radiation therapy.  
 
11. Known genetic disease or family history that may result in greater sensitivity to the effects of irradiation, or a physical deformity that would preclude adequate shielding or appropriate dosing during the irradiation component of the conditioning regimen.  
 12. Enrollment in other investigational drug studies within 30 days prior to enrollment.  
 13. Abnormal (> 2 × lab normal) values for (a) liver function chemistries (ALT, AST, AP), (b)  
bilirubin, (c) coagulation studies (PT, PTT).  
 14. Allergy or sensitivity to any component of ME DI-507, tacrolimus, or rituximab. 
 15. Maintenance immunosuppression within 3 months prior to conditioni ng other than physiological 
doses of steroids, defined as ≤ 50 mg of hydrocortisone or dose equivalent.  
 16.  The presence of any medical condition that the investigator deems incompatible with participation in the trial.  
 3.3 DONOR INCLUSION CRITERIA  
 Donors who meet the following criteria will undergo nephrectomy and bone marrow aspiration under 
general anesthesia. Sufficient marrow will be obtained to provide at least 2 × 108 nucleated cells per kilogram weight of the recipient.  
1.   Male or female 18 –65 years of age.  
 
2.   For females of childbearing potential: a serum pregnancy test showing negative results.  
 3.   Excellent health per conventional predonor history (medical and psychosocial evaluation).  
 4.   Acceptable laboratory parameters (hematology  in normal or near-normal range; liver function  
<2 times the upper limit of normal, and normal creatinine).  
 5.   Negative for viral infection with HbsAg, HIV, HCV, or HTLV -1. 
 6.   Cardiac/pulmonary function within normal limits (CXR, ECG).  
 7. Ability to un derstand and provide informed consent.  
 8. Meets standard institutional criteria for both bone marrow and kidney donation  
  3.4 PREMATURE DISCONTINUATION OF STUDY THERAPY  
 
3.4.1  Reasons for Premature Discontinuation of Study  Therapy  
 
 31 
 
Study therapy is defined  as initiation of any or all of the study medications or procedures described in 
section 5.  
 
Study therapy will be discontinued for the following reasons:  
 
• Hypersensitivity. If a participant develops a persistent hypersensitivity reaction to rituximab or MEDI-507 despite the measures described in sections 4.4.1, 4.4.1.2 , 4.4.3.1 and 4.4.3.3  
 
• Adverse experience. If a participant suffers from an adverse experience that, in the judgment of the principal investigator presents an unacceptable consequence or risk  to the participant. 
 
• Intercurrent illness or infection. If during the course of the study a participant develops an 
illness or infection that is not associated with the condition under study and that requires 
treatment not consistent with protocol requirements; or, if a participant develops an intercurrent illness that in the judgment of the principal investigator in any way justifies discontinuation.  
 
• Protocol violation. If a participant cannot comply with the study protocol, and the protocol deviations a re sufficient to jeopardize his or her well- being or the integrity of the study.  
 
3.4.2  Follow -up for Participants  Prematurely Discontinued  from  Study Therapy  
 
3.4.2.1   Safety Follow -up Assessments  
 All enrolled participants who discontinue study th erapy, regardless of outcome, will complete a safety 
follow -up. The following assessments will be performed at each safety follow -up visit:  
 
• Adverse events  
• Concomitant medications  
• Physical exam  
• Hematology  
• Serum and basic chemistries  
• Thyroid function  
• GVHD a ssessment  
• Graft survival  
• Chimerism  if still detectable at the previous visit  
 3.4.2.2   Safety Follow -up Visit Schedule  
 
Participants who discontinue study therapy will observe this visit schedule:  
 
• A visit 2 weeks after discontinuation  
• A visit every 4 w eeks for 24 weeks  
• A visit every 13 weeks for 78 weeks  
  
 32 
 
Participants in safety follow -up will have the option of scheduling a telephone visit in lieu of a clinic visit 
every other visit when the visits are 13 weeks apart.  
 
 3.5      PREMATURE TERMINATION F ROM THE STUDY  
 3.5.1     Reasons for Premature Termination from the Study   
 Participants will be prematurely terminated from the study for the following reasons:  
• Withdrawal of consent: If for any reason the participant withdraws consent during the study, the participant shall be terminated from the study.  
 
• Lost to follow -up: Participants who fail to return for visits and do not respond to repeated 
contact by the site staff are considered “lost to follow- up.” Realistic efforts will be made to 
locate these p articipants and ask them to continue in the study or to attend the study 
termination visit so that we may collect closeout study data.  
 
• Participants may only be replaced if they have been withdrawn from the study prior to receiving MEDI -507 and have had no study -related adverse events.  
 
3.5.2     Follow -up for Participants Prematurely Terminated from the Study  
 
Participants who wish to withdraw consent will be asked to complete the safety follow -up schedule 
specified in Section 3.4.2  
 Participants who are  prematurely terminated from the study during or after irradiation will be advised 
of the risk of cytopenias and will be advised to arrange to be followed, particularly during the 4 -week 
period following irradiation. Every attempt will be made to provide this follow -up for safety reasons, 
even if the participant has withdrawn consent.  
 
4.   STUDY MEDICATIONS AND PROCEDURES  
 
4.1 OVERVIEW OF CONDITIONING AND POST TRANSPLANT REGIMEN  
 
Participants  will receive  a conditioning regim en that starts  with  rituxi mab on days –7 ,– 2, 5, and 12, 
TBI on days –5 and –4. MEDI -507 will be administered  on days –2, –1, 0, and 1. Thymic irradiation  
will be given  on day–1, and co mbined  renal and bone  marrow  transplant  will be done  on day 0. 
Prednisone  will be started  at2 mg/kg on day 4 and  tapered  off by day  20. Tacroli mus will be 
administered  on days –1 through  60, and then tapered.  This regimen is depicted  in Figure  2.  
 
The recipients will have a tunneled central line placed on Day - 2 for study medication infusion and blood 
drawing. This will be removed post -transplant prior to discharge from the hospital.  
 
Proph ylaxis  will be provided  for PCP,  CMV,  and perioperative  infection.  All participants  who  require  a 
blood  transfusion  will receive  only  leukoc yte-depleted  and irradiated blood  products  for a period  of at 
least  52 weeks  following  transplant.  
 
 33 
 
 
4.2 DONOR BONE MARROW HARVEST AND NEPHRECTOMY 
 The donor will undergo nephrectomy and bone marrow aspiration under general anesthesia. Sufficient marrow will be obtained to provide at  least 2 × 108 nucleated cells per kilogram weight of the recipient.  
  4.3 LEUKAPHERESIS  
 Leukapheresis will be performed x1 on the recipient prior to initiating the conditioning regimen .  
  4.4 CONDITIONING REGIMEN  
 4.4.1  Rituximab  (Days  – 7,  –2,  5,  a nd  12)  
 Rituximab will be administered in a closely monitored setting by experienced staff knowledgeable about infusion reactions and their effective and timely management. There should be ready access to equipment and medications appropriate for managem ent of infusion reactions. In particular, 
medications and fluids for the rapid management of such reactions, including intravenous fluids, epinephrine, antihistamines, inhaled bronchodilators, and corticosteroids, should be readily available.
55 
 4.4.1.1  P retreatment  
 Acetaminophen 650 mg PO × 1, along with diphenhydramine 50 mg PO, and hydrocortisone 100 mg IV × 
1 will be given 30 minutes  prior to each dose of rituximab on days −7, 5, and 12. These premedications 
will not be given before the dose of rituximab on day −2, as the subject will be premedicated before the 
first dose of MEDI -507 on day −2.   
 4.4.1.2   Administration and Dosing   
 Rituxi mab will be supplied by the local investigational pharmacy. Instructions for preparation and 
administration can be found in the package insert at:  
http://www.gene.com /gene/products/information/pdf/rituxan -prescribing.pdf  
 
Rituximab (375 mg/m2/dose) will be administered on days – 7, –2, 5, and 12. Doses on d ays −7 and −2 
will be administered several hours after hemodialysis if hemodialysis is required. Start , stop times and 
dosage for administration will be recorded.  
 
The first rituximab solution for infusion will be administered intravenously at an initial rate of 50 mg/hour. Escalate the rate by 50 mg/hour every 30 minutes to a maximum of 400 mg/hour.  
 If hypersensitivity or an infusion- related event develops, the infusion should be temporarily slowed or 
interrupted. The infusion can continue at one -half th e previous rate upon improvement of the subject’s 
symptoms. 
 
The second dose of rituximab will be adminis tered on day −2, after 2 –3 hours of completing the first 
dose of MEDI -507 on day –2. If the first infusion was slowed or interrupted, the initial guidelines should 
 34 
 
again be followed. Otherwise, the second infusion may be started at 100 mg/hour and titrated  by 100 
mg/hour every 30 minutes to a maximum of 400 mg/hour.  
 
The third and fourth doses of rituximab will be administered in the same manner as the second dose.  
 
4.4.2  Low dose Total Body Irradiation  (Days  –5  and  – 4)  
 
4.4.2.1  Pretreatment  
Participants will be treated with anti- emetics as per institutional standard . 
 4.4.2.2   Administration   Total Body Irradiation of 150 cGy will be administered  on Day - 5 and Day -4 for a total dose of 300cGy. 
Radiation sources and dose rates will be per institutional standards  
 4.4.3  MEDI -507 
 4.4.3.1  Pretreatment  
 Steroid premedication with intravenous methylprednisolone sodium succinate, 8 mg/kg up to a maximum dose of 500 mg, along with diphenhydramine 50 mg PO, and acetaminophen 650 mg PO will be administered  prior to the first dose of MEDI -507 on day – 2 for prophylaxis of possible first dose 
reactions.  
 Diphenhydramine and acetaminophen may be administered at the discretion of the investigator 2 hours prior to the second and subsequent infusions of MEDI -507 o n days –1, 0, 1, but steroid premedication 
will not be given.  
 4.4.3.2   Administration and Dosing  
 MEDI -507 is supplied as a clear colorless solution and does not contain a preservative. MEDI -507 bulk 
biological substance was produced by MedImmune, Inc and validated by TGA Sciences Inc. The bulk 
solution was sterilized by filtration and aseptically filled into prewashed, presterilized, depyrogenized vials. MEDI- 507 is supplied at a concentration of  3.75 mg/mL in  4 mL vials that each contain 15 mg of 
MEDI -507. Sterile 0.9% normal saline for injection is used as diluent and supplied  by MGH . The 
instructions for dose preparation and administration are given in Appendix 5. 
 
MEDI -507 should be administered at approximately the same time each day, so that there  are 24 hours 
between doses.  MEDI -507 will be administered several hours after dialysis. The actual start and stop 
times of infusion will be recorded on the appropriate case report forms. If hypersensitivity or an infusion - related event develops, the inf usion should be temporarily slowed or interrupted. The infusion 
can continue at one -half the previous rate upon improvement of subject symptoms.  
 The first dose of MEDI- 507 (day –2) will be 0.1 mg/kg, administered over 30 minutes using an infusion 
pump. The prepared 0.1 -mg/kg dose will be supplied by the pharmacy to the investigator, who will 
administer the drug. The solution should be prepared to a final concentration of 0.1 –0.3 mg/mL (30 –100 
mL).  
 
 35 
 
The second and subsequent doses of MEDI -507 (days –1, 0, a nd 1) will be 0.6 mg/kg, administered over 
1 hour using an infusion pump. The day 0 infusion can be completed before or after transplant as long as 
it is consistent with the timing of the last dose. The prepared 0.6 -mg/kg dose will be supplied by the 
pharm acy to the investigator, who will administer the drug. For the second and subsequent doses, a 
concentration of 0.3 –1.8 mg/mL (50- to100 -mL infusion volume) is permitted.  
 The infusion may be administered using a peripheral vein, or a central line, if the latter is in place. Since the compatibility with other intravenously administered medications is not known, the MEDI -507 
solutions should not be infused through a common intravenous line used for other  
medications, unless the line is flushed prior to and after administration of MEDI -507. Precautions for 
“first -dose reactions” must be observed for the first and second doses of MEDI -507 (see section 4.4.3.3).  
 4.4.3.3  Management of Reactions to Rituximab and MEDI -507  
 “First -dose reactions” may occur upon the  initial administration of rituximab or MEDI -507. These have 
the potential to be severe. Prophylaxis against first -dose reactions is described above in sections 5.4.1. 
and 5.4.3. In addition, the following procedures will be followed in assessing the occurrence of such reactions, and to manage adequately any acute toxic manifestations.  
 Qualified personnel will observe each participant for a period of 2 hours after the administration of each of the first 2 doses of MEDI -507. Vital signs will be collected at  the end of each MEDI -507 infusion. A 
physician who is a member of the transplant team and who is familiar with this protocol must be available and in the facility throughout this time period. Additionally, a person who is expert in intubation must be on c all, in the facility, and available for 2 hours after the first and second doses of 
rituximab and MEDI- 507 in each subject. An emergency cart must be available. Participants must remain 
under observation for at least 2 hours after completion of the infusion of the first two doses of antibody.  
 Although acetaminophen and diphenhydramine are given prophylactically prior to administration of rituximab and MEDI- 507, further doses of acetaminophen (650 mg PO or PR) and diphenhydramine (50 
mg PO or IV) may be adm inistered if fever or chills occur post study drug administration. Temperature 
and other physical symptoms of the subject must be documented prior to administration of either medication. Corticosteroids (methylprednisolone, 250 mg IV)  may be administered i f a severe reaction 
occurs. All symptoms of drug reactions and treatment for drug reactions must be recorded on the appropriate case report forms.  
 
4.4.4  Thymic  Irradiation  (Day –1)  
 
The 700 cGy of thymic irradiation are administered in a single dose on  day –1. A field size of 
approximately 8 cm wide and 10 cm in longitudinal dimension will be used, with the midpoint of the upper edge of the field at the sternal notch. The dose will be calculated at a depth of approximately 6 cm, guided by results of a l ateral chest roentgenogram for the approximate location of the thymus. A 
10-MV machine at maximum dose rate should be used. No premedication for nausea should be 
required. The details regarding the field sizes, dose calculation, energy, beam spoiling, and dose rate will be recorded on the case report form.  
 
 
4.4.5  Tacrolimus  Administration  and  Dosing  (Day –1)  
 
 36 
 
Tacrolimus will be administered starting on day –1. The dose will be 0.05 mg/kg twice a day, and will be 
adjusted to provide a trough whole blood concentration of 8- 12 ng/mL. Substitution of generic forms of 
tacrolimus is not permitted. Tacrolimus will be continued at this level, then tapered as d escribed in 
section 5.4. 8. 
 
4.4.6 Prednisone (Days  4 –20,  22 –42)  and  Methylprednisolone  (Days 22 –42)  
 
To further mitigate possible symptoms of engraftment syndrome, prednisone will be started at 2 
mg/kg/day on day 4 and then tapered off by day 20.  
 Additional corticosteroids will be administered from days 22 to 42 if the participant meets any of the 
following criteria:  
 
1.   There has been no multilineage chimerism at any time post transplant.  
 
2.   There are clinical findings suggestive of  rejection and there is biopsy confirmation 
of renal allograft rejection of Banff grade IA or greater.  
 
4.4.7 ATG  Admin istration  in the event of Engraftment Syndrome   
 
During the second post -operative week, if the creatinine begins to increase  or the  donor chimerism 
begins to precipitously fall ( >50%), Tacrolimus w ill be discontinued and ATG  will be given. The  recipients 
can received up to 5 doses over a 10 day period during this time. Tacrolimus administration will be 
resumed after ATG is discontinued. Tacrolimus will subsequently  be withdrawn as detailed in section 
4.4.8.  
 4.4.7 .1 Preparation and Storage  
For information on the preparation, storage and handling of Thymoglobulin ®, please refer to the 
package insert for Thymoglobulin® (antithymocyte globulin [rabbit]) at the following website: 
http://www.thym oglobulin.com/home/thymo_pdf_pi.pdf  
 For information on the preparation, storage and handling of ATGAM, please refer to the package insert for Atgam® (lymphocyte immune globulin, anti -thymocyte globulin [equine]) at the following website:  
http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/license
dproductsblas/fractionatedplasmaproducts/ucm199603.pdf   
 4.4.7 .2 Pretreatment  
Before each dose of ATG, participants  will be pre -medicated with:  
• Methylprednisolone 100mg IV In addition participants will be pre -medicated with  
• Acetaminophen 650 mg PO and  
• Diphenhydrami ne 25 to 50 mg PO  
 
4.4.7.3 Administration and Dosage  
Participants may receive up to 5 intravenous doses of Thymoglobulin 1.5 mg/kg/dose or ATGAM 15mg/kg /dose  during a 10 day time period. This should be given on a QOD schedule.  
 The first dose of ATG should be infused over a minimum of 6 hours into a high -flow vein. The vein may 
be peripheral or central per investigator discretion. Subsequent doses should be infused over at least 4 
 37 
 
hours. ATG must be given under the supervision of appropriately trained med ical personnel. At any sign 
of any infusion related side effects, the infusion rate should be slowed by 50%. In the rare instance that 
anaphylaxis is reported with ATG use, the infusion should be terminated immediately and medical personnel should be avail able to treat patients who experience anaphylaxis 
 
 
4.4.8 Immunosuppression Withdrawal  
 
4.4.8.1   Eligibility Criteria for  Immunosuppression  Withdrawal  
 Tacrolimus will be tapered beginning 60 days post transplant if all of the following conditions are met:  
 
1.   There has been stable renal function (Cr < 2.0 mg/dL) for > 30 days, unless a transient rise in creatinine has been demonstrated to be clearly related to a known cause of renal dysfunction such as tacrolimus toxicity, a urologic complication, o ther 
drug toxicity, etc.  
 2.   There has been no evidence of Banff grade IA or greater rejection on a renal biopsy obtained within the past 4 weeks.   3.   There has been detectable multilineage white blood cell chimerism at any level. For this purpose, ch imerism will be assessed by flow cytometry.  
 4.   There has been no evidence of GVHD.  
 5.   There is no detectable antidonor HLA antibody.  
 Participants who do not meet these criteria the first time they are assessed will be reevaluated for withdrawal eligibility every 4 weeks.  
 Participants who do not meet withdrawal criteria by 78 weeks post transplant, however, will be considered ineligible for and to have failed immunosuppression withdrawal, and will begin safety follow -
up as described in Section 3.4.2 . 
 4.4.8.2   Pace and Time of Completion of Immunosuppression Withdrawal   
 
Participants will withdraw from tacrolimus over no less than 12 weeks.  
 
All withdrawal attempts will be completed no later than 104 weeks post transplant. Participants who do not com plete withdrawal by this time will be considered to have failed immunosuppression withdrawal, 
and will begin safety follow -up as described in Section 3.4.2. . 
 4.4.8.3   Follow -up During and After Immunosuppression Withdrawal   
  
Participants will be followed intensively for evidence of allograft rejection during and after the completion of withdrawal. A chemistry panel including serum creatinine will be measured : 
• Weekly during withdrawal and for 3 months after tacrolimus is discontinued   
• Every 2 weeks for 26  weeks  
• Monthly for 52 weeks  
 38 
 
 
4.4.8.4   Immunosuppression Withdrawal after Episodes of Rejection  
 Participants who experience rejection prior to completion of immunosuppression withdrawal will be permitted to resume immunosuppression withdrawal only if th ey fulfill the following criteria:  
 1.   Stability on maintenance calcineurin inhibitor monotherapy for at least 60 days.  
 2.   A renal biopsy that demonstrates the absence of rejection, defined as less than Banff grade IA.  
  4.4.8.5   Follow -up and Treatment for Participants who Fail Immunosuppression Withdrawal  
 Participants who have failed immunosuppression withdrawal will begin safety follow -up as detailed in 
3.4.2.2. 
 
Participants in safety follow -up will have the option of scheduling a telephone visi t in lieu of a clinic visit 
every other visit when the visits are 13 weeks apart.  
 Participants who fail immunosuppression withdrawal will be treated according to institutional standard at the discretion of the investigator.  
 Participants who experience rejection following completion of immunosuppression withdrawal will be permitted to restart immunosuppressive therapy and attempt withdrawal at a slower pace. If such participants experience a second episode of rejection at any time during the second attempt, they will 
not be allowed to undergo further immunosuppression withdrawal. They will be considered to have 
failed immunosuppression withdrawal and will begin safety follow -up as described in Appendix 7.  
  4.5 TRANSPLANT PROCEDURES  
 4.5.1  Bone Marrow Transplant ( Day 0)  
 4.5.1.1  Preparation and Characterization of Bone Marrow Product  
 
Donor bone marrow (> 1.5 × 10
8 nucleated cells /kg of recipient body weight) is prepared for infusion 
and characterized as outlined below. In the situation of minor ABO incompatibility, plasma will first be 
removed following centrifugation of the product. The bone marrow sample will be characterized as to the total volume, total nucleated cell content, total CD3+ T- cell content, and total CD34+ cell content.  
 4.5.1.2  Infusion  Procedures  
 Allogeneic bone marrow will be rapidly infused intravenously without a filter as soon as possible  
after harvest. A total of 15,000 units of heparin is mixed with the marrow, which is infused at a rate of  
300-500 mL/hour. The infusion begins in  the operating room as soon as the vascular anastomosis of the 
renal allograft has been completed.  
 
 39 
 
Protamine, 25 mg, is administered IV after completion of the first half of the bone marrow infusion. If a 
partial thromboplastin time measured after completion of the marrow infusion is greater than  
60 seconds, the Protamine treatment will be repeated.  
 4.5.2  Renal Transplant ( Day 0)  
 Prophylactic antimicrobial therapy will be administered prior to surgery according to institutional practice.  
 4.5.2.1  Surgi cal Procedure  
 The renal transplant is performed according to standard surgical techniques. A ureteral stent should be placed if surgically feasible.  
 4.5.2.2   Intra -operative  Renal  Biopsy  
 A wedge biopsy will be obtained on the day of transplant  and sent for routine pathology diagnostics 
(please refer to section 5.4.2).  
 4.6 PROPHYLAXIS AGAINST AND TREATMENT OF INFECTION  
 4.6.1  Pneumocystis and Urinary  Tract Infections   
 Trimethoprim and Sulfamethoxazole (TMP/SMX), one single - or double -strength table t daily will be 
administered to all participants starting at the initiation of t he conditioning regimen (day −7) and 
continuing until the day of transplantation. It will be restarted the day neutrophil counts exceed  
500/µL and continued until 24 weeks post transplant.  
 In the event of allergy or intolerance to the components of TMP/SM X, atovoquone, 1.5 g PO each day 
will be used in its place for prophylaxis of Pneumocystis carinii.  
 Consideration will be given to extending the period of prophylaxis for an additional 6 months if it is felt to be clinically indicated, since TMP/SMX provides prophylaxis against the majority of isolates of pneumococcus and H. influenza.  
 
Levofloxacin, 250 –500 mg daily (as a suitable quinolone substitute), will be started at the onset of 
neutropenia (ANC <0.5) and continued until resolution of the neutropeni a (ANC >0.5).  
 
4.6.2  Fungal and Yeast Infections   
 Post -transplant prophylaxis for fungal infections will be administered at the discretion of the 
investigator.  
 4.6.3  CMV Infection  
 
4.6.3.1   Prophylaxis  When  at  Least  One  of  the  Donor –Recipient  P air  is  Seropositive  
 
 40 
 
Cytomegalovirus prophylaxis is central to the successful outcome of BMT and organ transplantation. All 
BMT participants should receive seronegative or CMV “safe” blood (leukofiltered). The greatest risk for CMV infection in solid organ transplantation is for the donor seropositive (D+) into recipient seronegative (R−) combination. In hematopoietic stem -cell transplantation, CMV pneumonitis is most 
common in the D− into R+ combination. Given that CMV infection may occur in any combina tion in 
which at least one of the donor –recipient pair is seropositive, a uniform approach for such cases is most 
reasonable in terms of preventing invasive infection. To this end, each recipient under this protocol will:  
 1.   Have the serologic status ob tained for donor and recipient.  
 2.   Be monitored weekly by quantitative CMV DNA PCR assay while neutropenic and following engraftment.  
 3.   Receive G anciclovir 5 mg/kg × 1 dose prior to renal transplantation (day −1).  
 
4.   Subsequently receive CMV prophylaxis per institutional standards after the ANC exceeds  
1000.  
 
4.6.3.2   Prophylaxis in Individuals when Donors -Recipients are both Seronegative  
 Provided CMV -negative pedigreed blood products are utilized, there is a very low risk of CMV disease 
when both donor and recipient are seronegative. Therefore, in such cases, CMV prophylaxis will not be given. To prevent the 40% incidence of herpes simplex d isease that occurs in transplant patients not 
receiving ganciclovir, oral acyclovir 400 mg TID or other approved antiviral therapy will be prescribed for 4–6 months.  
 4.6.3.3   Treatment of CMV Infection  
 Initial treatment of CMV disease (defined by CMV PC R) is for a minimum of 2 –3 weeks with intravenous 
ganciclovir at a dose of 5 mg/kg twice daily (with dosage adjustment for renal dysfunction), oral valganciclovir 900 mg PO BID, or other approved antiviral medication per institutional standards. CMV IgG (1 50 mg/kg q 4 weeks) will be added for seronegative participants  
at the discretion of the investigator. The endpoint of intravenous therapy is the documented clearance of virus from the blood as demonstrated by CMV antigenemia assay or quantitative PCR assay.  
 
The risk of subsequent relapse is ~15% –20%, so treatment will be continued for at least 3 months. With 
3 months of oral therapy following clearance of viremia, the rate of relapse is decreased substantially.  
 
In participants with relapsing infection, initial treatment is repeated. CMV hyperimmune globulin (at a dose of 150 mg/kg IV once and 100 mg/kg IV q month × 3 –6) is usually administered in conjunction with 
the intravenous ganciclovir, oral valganciclovir or other approved therapy for seronegative r ecipients at 
the discretion of the investigator. Treatment will be maintained in the setting of active GVHD.  
 Table 2. Dosing nomogram for treatment of CMV infection  
 
Serum Creatinine  
(mg/dL)  Intravenous Dose  
(mg/kg)   
Frequency  
<2.0  5 Q12h  
 41 
 
2–3 5 Daily  
3–5 1.25  Daily  
>5.0  1.25*  QOD  
Hemodialysis  5 Post dialysis  
Peritoneal dialysis  2.5*  Daily  
 
 *After a loading dose of 5 mg/kg. All patients (prophylaxis or therapeutic) receive leukocyte or CMV -
negative blood; CMV -hyperimmune globulin (Massachusetts Red  Cross) 150 mg/kg IV for the first dose 
and 100mg/kg × 4 at the discretion of the physician.  
 4.6.4  Herpes  Infection  
 CMV prophylaxis as described in section 4.6.3 will also serve as prophylaxis against herpes infection.  
 4.7 ASSESSMENT OF ALLOGRAFT DYSF UNCTION AND TREATMENT OF RENAL REJECTION 
 4.7.1  Definition of Allograft Dysfunction and Indication for Biopsy  
 Renal allograft dysfunction is defined as an increase in creatinine of 25% or greater compared to the 
baseline creatinine post transplant. Baseline is defined as an average of the 3 lowest creatinines during 
weeks 2 -4 post transplant, excluding days on dialysis.   
 If allograft dysfunction is unexplained and persists for greater than 72 hours, a renal biopsy must be performed to rule out acute rejection. If the biopsy does not demonstrate rejection, further evaluation for other causes of renal dysfunction will be performed.  
 4.7.2  Diagnosis, Grading and Monitoring of Rejection  
 Renal allograft biopsies will be used to diagnose and grade rejection. Biopsies will be assigned a Banff 
grade according to the most current Banff Classification of Renal Allograft Pathology.  
 
4.7.2.1  Humoral (Antibody -mediated) Rejection  
 Humoral rejection is defined according to the Banff Classification of Renal Allograft Pathology (see  
Appendix 2).  
 4.7.2.2   Acute Cellular Rejection  
 A Banff score of grade IA or above will constitute acute cellular rejection (see Appendix 2).  
 4.7.2.3   Chronic Rejection  
 Chronic rejection (both humoral and cellular) is defined according  to the Banff Classification of  
Renal Allograft Pathology (see Appendix 2).  
 4.7.3  Treatment of Rejection   
 42 
 
 
If participants show evidence of graft rejection, standard rejection therapy will be initiated according to institutional protocol. Specific therapy  for rejection may include any or all of the following: Solumedrol, 
Thymoglobulin, Campath, or other antilymphocyte antibody therapies and local irradiation of the kidney allograft. Plasmapheresis, IVIg, Rituximab and Velcade  may be utilized if humoral rej ection is diagnosed. 
A renal biopsy will be performed within 14 days of completion of treatment for rejection to document response to therapy. After biopsy confirmation of resolution of rejection, the participant will be weaned to maintenance therapy as de fined by institutional practices. Maintenance therapy may include any or 
all of the following medications: tacrolimus, cyclosporine, sirolimus, steroids, azathioprine, and/or MMF. It is recognized that graft failure and return to dialysis may occur despite  these measures, and such an 
outcome will be included in the consent forms and discussed with the participant.  
 For participants with findings “suspicious” for acute cellular rejection (less than grade IA rejection), additional maintenance immunosuppressiv e therapy will not be instituted even if they are treated for 
rejection based on clinical need. However, these participants will be rebiopsied within 3– 4 weeks, 
closely monitored for further histological or clinical evidence of rejection, and considered fo r 
subsequent tacrolimus taper and discontinuation.  
 For participants who receive antilymphocyte antibody therapy, antiviral and antipneumocystosis prophylaxis will be administered for an additional 10 weeks at the discretion of the investigator.  
 4.8 PROH IBITED MEDICATIONS 
 No concomitant immunosuppressants aside from rituximab and MEDI -507 (or others specified in this 
protocol) may be administered during the conditioning regimen. If such therapy is required, the 
conditioning regimen must be stopped, and t he participant will be considered to have prematurely 
discontinued study therapy (section 4.4). The administration of any live  or investigational vaccine is 
prohibited for all participants on the study from 30 days prior to transplantation (day −30) until 60 days 
following transplantation (day 60).  
 
4.9 DRUG ACCOUNTABILITY  
 Under Title 21 of the Code of Federal Regulations (21CFR §312.62) the investigator is required to maintain adequate records of the disposition of the investigational agent, including the  date and 
quantity of the drug received, to whom the drug was dispensed (participant -by-participant accounting), 
and a detailed accounting of any drug accidentally or deliberately destroyed. Records for receipt, storage, use, and disposition will be maintained by the study site. A drug- dispensing log containing the 
patient identification number and the date and quantity of drug dispensed will be maintained for each participant.  
 5. STUDY PROCEDURES  
 5.1 GENERAL ASSESSMENTS  
 Informed consent: Written informed consent will be obtained before any study -related assessments or 
procedures are performed.  
 
• Physical examination  
 43 
 
o At Screening  
o At each inpatient or outpatient visit  
• Medical history: Medical history will include psychosocial evaluation and previous transp lant 
history  
o At Screening  
• Cardiac function —echocardiogram.  
o At Screening  
• Pulmonary function —chest x -ray and PFTs ( DLCO, spirometry & Lung volumes)  
o At Screening  
• GVHD: GVHD will be staged and graded as in Appendix 3.  
o Daily while hospitalized  
o At each outpatien t visit until chimerism undetectable  
• Leukapheresis  
o Prior to Day -7 
• Protocol Renal biopsy  
o Day 10  
o Month 6  
o Month 9  
o Year 1  
o Year 2  
o Year 3  
 
 5.2 LABORATORY ASSESSMENTS 
 
• Hematology —CBC with differential and platelets  
o At Screening  
o Daily while hospitalized  
o At each outpatient visit  
• Serum chemistry —ALT, AST, BUN, AP, bilirubin, albumin, total protein  
o At Screening  
o Weekly while hospitalized  
o At each outpatient visit  
• Basic chemistry —electrolytes, glucose, BUN, and creatinine  
o Daily while hospitalized  
o At each outpatient vis it 
o See section 4.9.3 for monitoring during and after immunosuppression withdrawal  
• Coagulation studies —PT/INR and PTT  
o At screening 
o Week 1  
o Day 10 (with biopsy)  
o Month 9 (with biopsy)  
o Every  6 months thereafter   
• Thyroid function —T3, FT4, and TSH 
o At Screening  
o Every 6 months thereafter  
• Serum pregnancy test  
 44 
 
o At Screening  
• HLA typing – by intermediate resolution for  HLA- A, B, C, DRB1, DQA1 and DQB1   
o At Screening  
• ABO typing  
o At Screening  
• T and B Cell  crossmatch  by Flow Cytometry and Cytotoxicity  
o At Screening  
• HLA alloan tibodies per routine methodology (AHG and/or ELISA)  
o At Screening  
o Prior to Initiation of Day - 7 Treatment  
o Weekly - Weeks 1 -6 
o Every other month for 3 years  
o Year 4  
o Year 5  
• Viral and syphilis serology –CMV IgG, HIV  I/II, HbsAg, HbsAb, HCV, EBV, and syphilis  
o At Screening  
• Tacrolimus levels  
o Daily  Post -Transplant  while hospitalized  
o At each outpatient visit  
o May discontinue when level is undetectable after immunosuppression withdrawal  
• BK virus PCR (blood)  
o Week 1  
o Every other month thereafter  
• Chimersim  
o 2x/ Week  start ing on Day 7  until  chimerism is undetectable  
• Research Testing  
This is a 2 patient pilot trial, no funding is provided for in vitro research studies. A minimal volume of 
blood (< 40 cc / week) will be drawn and stored for potential future research studies. If the 
leukapheresis that is collected pre -transplant is not used to treat GVHD, this will be used for 
potential future research studies as well.  
  5.3 RENAL BIOPSY  
 
5.3.1. RENAL CORE BIOPSIES  
 
Participants will undergo surveillance renal core biopsies Day 10- 12, 6 months, 1 Year, 2 Years and 3 
Years post transplant. These biopsies will be used to monitor function and to screen for subclinical 
rejection.  
 5.3.2  INTRA -OPERATIVE WEDGE BIOPSY  
 A 3 × 5 -mm wedge biopsy will be obtained on the day of transplan t to assess for any evidence of donor 
disease.  
 
5.3.3   For -cause Biopsies  
 
 45 
 
For-cause biopsies will be obtained to confirm suspected rejection following unexplained allograft 
dysfunction.  
 
6. ADVERSE EVENTS  
 
6.1 OVERVIEW  
 
This section defines the types o f adverse events and outlines the procedures for appropriately 
collecting, grading, recording, and reporting them. Information in this section complies with ICH  
Guideline E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, ICH Guideline E -6: Guideline for Good Clinical Practice, and applies the standards set forth in the National 
Cancer Institute (NCI), Common Terminology Criteria for Adverse Events, Version 4.0 (May 28, 2009).  
 6.2 DEFINITIONS  
 
6.2.1 Adverse Event  
 
An adverse event is any occurrence or worsening of an undesirable or unintended sign, symptom, 
laboratory finding, or disease that occurs during participation in the trial.  
 An adverse event will be followed until it resolves or until 30 days after a participant terminates from the study, whichever comes first.  
 6.2.2 Serious Adverse Event  
 
An SAE or reaction is defined as any adverse event that suggests a significant hazard, contraindication, 
side effect, or precaution. This includes but is not limited to an y of the following events:  
 
• Death: A death that occurs during the study or that comes to the attention of the investigator during the protocol -defined follow -up after the completion of therapy must be reported 
whether it is considered treatment related or not.  
 
• A life -threatening event: A life -threatening event is any adverse therapy experience that, in the 
view of the investigator, places the participant at immediate risk of death from the reaction as it occurred.  
 
• Inpatient hospitalization or prolongation  of existing hospitalization.  
 
• Persistent or significant disability.  
 
• An event that requires intervention to prevent permanent impairment or damage. An important medical event that may not result in death, be life threatening, or require hospitalization may be considered an SAE when, based on appropriate medical judgment, it may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed above.  
 
• Congenital anomaly or birth defect.  
 46 
 
 
Regardless of the relation of the adverse event to study participation, the event must be reported as a serious adverse event if it meets any of the above definitions.  
 6.2.3 Unexpected Adverse Event  
 An adverse event is considered “unexpected” when its nature or severity is not consistent with applicable product information described in the safety information provided in the investigator’s brochure for MEDI -507 or package inserts for study medications in section 4 . The package inserts that 
apply are those for Rituxan (rituximab), Thymoglobulin , ATGAM,  prednisone , Prograf (tacrolimus).  
 6.3 COLLECTING ADVERSE EVENTS  
 Adverse events will be collected from the time the participant is enrolled until 30 days after the participant completes the study. Prior to the beginning of study treatment, only adverse events related 
to screening assessments will be reported.  
 
Adverse events may be discovered through any of these methods:  
 
• Observing the participant.  
 
• Questioning the participant in an objective manner.  
 
• Receiving an unsolicited com plaint from the participant.  
 An abnormal value or result from a clinical or laboratory evaluation (e.g., a radiograph, an ultrasound, or an electrocardiogram) can also indicate an adverse event. If this is the case, then the evaluation  
that produced the v alue or result should be repeated until that value or result returns to normal or can 
be explained and the participant’s safety is not at risk. If an abnormal value or result is determined by the investigator to be clinically significant, it must be recorded as an adverse event on the appropriate case report form(s).  
 The investigator will treat participants experiencing adverse events appropriately and observe them at suitable intervals until their symptoms resolve or their status stabilizes.  
  6.4 GRADING , ATTRIBUTION AND REPORTING OF ADVERSE EVENTS  
 6.4.1 Grading  Criteria  
 The study site will grade the severity of adverse events experienced by ITN study participants according 
to the criteria set forth in the National Cancer Institute’s Common Toxicity Criteria for Adverse Events 
Version 4.0 (published May 28, 2009). This document (referred to herein as the NCI -CTCAE manual) 
provides a common language to describe levels of severity, to analyze and interpret data, and to articulate the clinical significance of all adverse events. For additional information and a printable version of the NCI -CTCAE manual, consult the NCI -CTCAE web site: 
http://ctep.cancer.gov/reporting/ctc.html.  
 
 47 
 
Adverse events will be graded on a scale from 1 to 5 according to the following standards in the NCI - 
CTCAE manual:  
 
Grade 1 = mild adverse event.  
 
Grade 2 = moderate adverse event.  
 
Grade 3 = severe and undesirable adverse event.  
 Grade 4 = life -threatening or disabling adve rse event.  
 Grade 5 = death.  
 6.4.2 Attribution  Definitions  
 
Adverse events will be categorized for their relation to each of the following: 
 
• MEDI -507 
• Total Body Irradiation  
• Rituximab  
• Tacrolimus (or other CNI)  
• Other study medications and procedures  
 The relation, or attribution, of an adverse event to MEDI -507 and other study medications and 
procedures will be determined by the site investigator. The investigator will also record the  
determination of attribution on the appropriate CRF and/or SAE reporting form. The relation of an 
adverse event to MEDI -507 or other study medications and procedures will be determined using the 
descriptors and definitions provided in Table 6.  
 
Table 3. Attribution of adverse events  
 
Code  Descriptor  Definition  
Unrelated Categ ory 
1 Unrelated  The adverse event is clearly not related.  
Related Categories  
2 Unlikely  The adverse event is doubtfully related.  
3 Possible  The adverse event may be related.  
4 Probable  The adverse event is likely related.  
5 Definite  The adverse event  is clearly related.  
 
 6.4.3.   Adverse Event  Reporting Requirements   
 
Adverse events that are <  Grade 2 will not be reported.  
  7. STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN  
 48 
 
 
7.1 ANALYSIS SAMPLES  
 Given a sample size of 2 participants, the analyses will be descriptive. However, to the extent possible, 
estimates obtained in the study will be interpreted in the context of the data from historical cohorts.  
 8. Q UALIT Y CONTRO L AND QUALIT Y ASSURANCE   
The investigator  is required  to keep  accurate  records to ensure  that the conduct  of the study  is fully 
docu mented.   
 
 9. ETHICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL PRACTICE  
  9.1 STATEMENT OF COMPLIANCE  
 This trial will be conducted in compliance with the protocol, with current good clinical practices  
(GCP), the principles of the Declaration of Helsinki, and with all applicable regulatory requirements.  
 
Before study initiation, the protocol and the informed consent documents will be reviewed and 
approved by an appropriate ethics review committee or institutional review board. Any amendments to the protocol or to the consent materials must also be approved before they are implemented.  
  9.2 INFORMED CONSENT  
 The informed consent form is a means of providing information about the trial to a prospect ive 
subject and allows for an informed decision about participation in the study. All participants (or their 
legally acceptable representative) must read, sign, and date a consent form before entering the study, 
taking study drug, or undergoing any study -specific procedures. Consent materials for participants who 
do not speak or read English must be translated into the participants’ appropriate language.  
 The informed consent form must be revised whenever important new safety information is available, whene ver the protocol is amended, and/or whenever any new information becomes available that may 
affect participation in the trial.  
 A copy of the informed consent will be given to a prospective participant for review. The attending physician, in the presence o f a witness, will review the consent and answer questions. The prospective 
participant will be told that being in the trial is voluntary and that he/she may withdraw from the study at any time, for any reason.   9.3 PRIVACY AND CONFIDENTIALITY  
 A participant’s privacy and confidentiality will be respected throughout the study. Each participant will be assigned a sequential identification number, and these numbers rather than names will be used to collect, store, and report participant information.  
 49 
 
 
  References  
 
1. Murray JE, Merrill JP, Harrison JH. Kidney transplantation between seven pairs of identical twins. Ann 
Surg 1958;148(3):343- 59. 
2. Lodhi SA, Lamb KE, Meier -Kriesche HU. Solid organ allograft survival improvement in the United 
States: the long -term does not mirror the dramatic short -term success. Am J Transplant;11(6):1226 -35. 
3. Meier -Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival 
despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4(3):378- 83. 
4. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005;16(2):496 -506.  
5. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2(9):807 -18. 
6. Morales JM, Dominguez -Gil B. Cardiovascular risk profile with the new immunosuppressive 
combinations after renal transplantation. J Hypertens 2005;23(9):1609 -16. 
7. Dharnidharka VR, Caillard S, Agodoa LY, Abbott KC. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006;81(12):1662 -7. 
8. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantatio n: 
current epidemiology and associated risk factors. Clin Transplant 2006;20(4):401 -9. 
9. Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL. Rates of first infection following kidney transplant in the United States. Kidney Int 2009;75(3):317 -26. 
10. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69(16):2227 -43. 
11. Rama I, Grinyo JM. Malignancy after renal transplantation: the ro le of immunosuppression. Nat Rev 
Nephrol;6(9):511 -9. 
12. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89(7):1221 -7. 
13. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346(8972):403 -6. 
14. Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs cyclosporine -treated 
kidney transplant recipients. Transplant Proc 1991;23(6):3169 -70. 
15. Jindal RM, Sidner RA, Milgrom ML. Post -transplant diabetes mellitus. The role of 
immunosuppression. Drug Saf 1997;16(4):242- 57. 
16. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000;23(7):482 -90. 
17. Je vnikar AM, Petric R, Holub BJ, Philbrick DJ, Clark WF. Effect of cyclosporine on plasma lipids and 
modification with dietary fish oil. Transplantation 1988;46(5):722 -5. 
18. Nemunaitis J, Deeg HJ, Yee GC. High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet 1986;2(8509):744- 5. 
19. Abouljoud MS, Levy MF, Klintmalm GB. Hyperlipidemia after liver transplantation: long -term results 
of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. Transplant Proc 1995;27(1):1121 -3. 
20. McCune TR, Thacker LR, II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful 
renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. 
Transplantation 1998;65 (1):87 -92. 
 50 
 
21. Ponticelli C, Campise MR. Neurological complications in kidney transplant recipients. J Nephrol 
2005;18(5):521 -8. 
22. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl 2001;7(11):937 -42. 
23. Kasiske BL, Snyder JJ, Gilberts on DT, Wang C. Cancer after kidney transplantation in the United 
States. Am J Transplant 2004;4(6):905- 13. 
24. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression - de novo malignancy 
after renal transplantation: the experience of t he Transplantation Center Munich. Kidney Int 
2007;71(12):1271- 8. 
25. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002;347(2):103 -9. 
26. Lonze BE, Warren DS, Stewart ZA , et al. Kidney transplantation in previous heart or lung recipients. 
Am J Transplant 2009;9(3):578 -85. 
27. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004;4(3):438 -43. 
28. Lodhi SA, Meier -Kriesche HU. Kidney allograft survival: the long and short of it. Nephrol Dial 
Transplant;26(1):15 -7. 
29. Pascual M, Theruvath T, Kawai T, Tolkoff- Rubin N, Cosimi AB. Strategies to improve long- term 
outcomes after renal transplantation. N Engl J Med 2002;3 46(8):580- 90. 
30. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63(2):243 -9. 
31. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operatio nal 
tolerance after pediatric living- donor liver transplantation. Transpl Immunol 2007;17(2):94 -7. 
32. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989;169(2):4 93-502.  
33. Sykes M, Sachs DH. Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 2001;356(1409):707- 26. 
34. Fuchimoto Y, Huang CA, Yamada K, et al. Mixed chimerism and tolerance without whole body irradiation in a large animal model. J Clin Invest 2000;105(12):1779- 89. 
35. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995;59(2):256 -62. 
36. Kawai T, Poncelet A, Sachs DH, et al. Long -term outcome and alloantibody produc tion in a non -
myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999;68(11):1767 -75. 
37. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004;4(9):1391 -8. 
38. Spitzer TR, Delmonico F, Tolkoff -Rubin N, et al. Combined histocompatibility leukocyte antigen -
matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal 
disease: the indu ction of allograft tolerance through mixed lymphohematopoietic chimerism. 
Transplantation 1999;68(4):480- 4. 
39. Spitzer TR, Sykes M, Tolkoff -Rubin N, et al. Long- Term Follow -Up of Recipients of Combined Human 
Leukocyte Antigen -Matched Bone Marrow and Kidne y Transplantation for Multiple Myeloma With End-
Stage Renal Disease. Transplantation.  
40. Kawai T, Cosimi AB, Spitzer TR, et al. HLA -mismatched renal transplantation without maintenance 
immunosuppression. N Engl J Med 2008;358(4):353 -61. 
41. Ildstad ST, Sa chs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow 
leads to specific acceptance of allografts or xenografts. Nature 1984;307(5947):168 -70. 
42. Sharabi Y, Sachs DH. Engraftment of allogeneic bone marrow following administration of anti-T cell monoclonal antibodies and low -dose irradiation. Transplant Proc 1989;21(1 Pt 1):233 -5. 
 51 
 
43. Wekerle T, Sayegh MH, Ito H, et al. Anti- CD154 or CTLA4Ig obviates the need for thymic irradiation in 
a non -myeloablative conditioning regimen for the  induction of mixed hematopoietic chimerism and 
tolerance. Transplantation 1999;68(9):1348 -55. 
44. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the 
conditioning regimen for achieving mixed chimerism and donor -specific tolerance in cynomolgus 
monkeys. Transplantation 1997;64(5):709 -16. 
45. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J E xp Med 
1998;187(12):2037- 44. 
46. Scandling JD, Busque S, Dejbakhsh -Jones S, et al. Tolerance and chimerism after renal and 
hematopoietic -cell transplantation. N Engl J Med 2008;358(4):362 -8. 
47. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med 2011;365(14):1359 -60. 
48. Leventhal J, Abecassis M, Miller J, et al. Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA -Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation. Sci 
Transl Med 2012;4(124):124ra28.  
49. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001;14(4):417 -24. 
50. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablat ive marrow transplantation: in vivo and in vitro analyses. Am J Transplant 
2006;6(9):2121- 33. 
51. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence 
for early donor- specific unresponsiveness in patients receivi ng combined kidney and bone marrow 
transplantation to induce tolerance. Transplantation;90(12):1607 -15. 
52. Farris AB, Taheri D, Kawai T, et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts . Am J Transplant 2011;11(7):1464 -77. 
 
 52 
 
 
Appendix 1. Diagnosis and Classification of Selected Opportunistic Infections  
 Cytomegalovirus Infections  
 
1.   Seroconversion: Change from CMV seronegative status to seropositive after transplantation as 
determined by an accepted serologic test, using the manufacturers criteria for seroconversion. The type of test used should be specified.  
 2.   Shedding (urine, throat): A positive culture, whether conventional or by rapid antigen test  
(“shell vial”), without evide nce of clinical disease.  
 3.   Viremia or antigenemia: A positive culture from blood or buffy coat, whether by conventional culture, or rapid antigen test (“shell vial”), or immunochemical testing.  
 
4.   Disseminated/syndrome: A positive culture from blood  or buffy coat, or another site, as above, in 
association with a compatible clinical illness consisting of fever and leukopenia, with or without liver 
function test abnormalities.  
 5.   End organ disease (specify site): Clinical signs plus a positive culture of a normally sterile site, preferably the organ involved, or positive histology with appropriate clinical signs (gut, lung, retina, liver, etc.). Must be considered presumptive if positive clinical signs or laboratory test results are found, but no def initive evidence of viral invasion is present (positive culture, presence of antigen, positive 
histology).  
 
Herpes Zoster Infections  
 
1.   Localized: Dermatomal distribution of a single or 2 adjacent dermatomes with no crossing the midline.  
 2.   Skin diss emination: Lesions in more than 2 dermatomes, crossing the midline, or multiple isolated 
lesions on the skin, with no evidence of internal organ involvement (e.g. brain, lungs, liver, gut, peritoneum).  
 3.   Disseminated: Internal organ involvement by hist ology or compatible clinical syndrome with 
characteristic skin involvement.  
 Candida Infections  
 1.   Mucosal: Mucosal involvement (oropharynx, GU tract) without systemic signs or symptoms attributable to Candida.  
 2.   Candidemia: Positive culture of blood or intravenous access device tip, with or without fever.  
 3.   Invasive: Positive culture of a normally sterile site, or positive histologic evidence of tissue invasion 
(skin [hematogenous], gut, liver, spleen, retina, lung, kidney), including positive blood culture in absence 
of an infected intravenous device.  
 53 
 
Appendix 2. Current Banff Classification of Renal Allograft Pathology (Banff 2007 )1 
 
 1. Normal  
2. Antibody -mediated changes (may coincide with catagories 3, 4 and 5 and 6)  
 
Due to documentation of circulating antidonor antibody, C4d,
1 and allograft 
pathology  
 
C4d deposition without morphologic evidence of active rejection  
 C4d+, presence of circulating antidonor antibodies, no signs of acute or chronic TCMR or ABMR (i.e. g0, cg0, ptc0, no ptc lam ination (<5 layers by electron 
microscopy), no ATN -like minimal inflammation ). Cases with simultaneous 
borderline changes are considered as indeterminate  
  
Acute antibody -mediated rejection2 
C4d+, presence of circulating antidonor antibodies, morphologic evidence of acute tissue injury, such as 
(Type/Grade)  
Type I. ATN -like minimal inflammation 
Type II. Capillary and or glomerular inflammation (ptc/g >0) and/or thromboses  
Type III. Arterial —v3 
 
Chronic active antibody -mediated rejection2  
C4d+, presence of circulating antidonor antibodies, morphologic evidence of chronic tissue injury, such as glomerular double contours and/or peritubular capillary basement membrane multilayering and/or interstitial fibrosis/tubular atrophy and/or fibrous intimal thickening in arteries  
 3. Borderline changes: ‘Suspicious’ for acute T -cell mediated rejection (may coincide with categories 2 
and 5, and 6)  
 This category is used when no intimal arteritis is present, but there are foci of tubulitis (t1, t2 or t3) with minor interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis  
 
4. T-cell mediated rejection (TCMR, may coincide with categories 2 and 5 and 6)  
 
Acute T- cell mediated rejection (Type/Grade:) : 
 IA. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of moderate tubulitis (t2)  
IB. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of severe tubulitis (t3)  IIA. Cases with mild to moderat e intimal arteritis (v1)  
IIB. Cases with severe intimal arteritis comprising >25% of the luminal area (v2)  
III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation (v3)  
 54 
 
 
Chronic active T -cell mediated rejection  
‘chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, formation of neo  -intima)  
 
5. Interstitial fibrosis and tubular atrophy, no evidence of any  specific etiology  
 (may include nonspecific vascular and glomerular sclerosis, but severity graded by tubulointerstitial 
features)  
 
 Grade  
I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area)  
II. Moderate interstitial fibrosis and tubular atrophy (26 –50% of cortical area)  
III. Severe interstitial fibrosis and tubular atrophy/ loss (>50% of cortical area)  
 6. Other: Changes not considered to be due to rejection - acute and/or chronic (For diagnoses see table 
14 in (49); may include isola ted g, cg, or cv lesions and coincide with categories 2, 3, 4, and 5)  
  
1Please refer to Banff 2007 classification paper http://onlinelibrary.wiley.com/doi/10.1111 /j.1600-
6143.2009.02987.x/abstract  
 
2Suspicious for antibody -mediated rejection if C4d (in the presence of antibody) or alloantibody (C4d+) 
not demonstrated in the presence of morphologic evidence of tissue injury.  
  
B. Sis
1,2,*, M. Mengel1,2, M. Haas3,R. B. Colvin4, et al., Banff ’09 Meeting Report: Antibody Mediated Graft 
Deterioration and Implementation of Banff Working Group. Am J Transplant, 2009;10:464 -471  
http://onlinelibrary.wiley.com/doi/10.1111/j.1600 -6143.2009.02987.x/abstract  
 55 
 
 
Appendix 3. Staging and Grading of Graft -Versus- Host Disease  
 Organ Staging of Graft -Versus -Host Disease  
 
 
Stage   
Skin  
Liver   
Gut 
1 Maculopapular rash, <25%  
of body surface a Bilirubin  
2–3 mg/dL b 500–999 mL diarrhea/day c, or persistent 
nausea with histologic evidence of GVHD 
in stomach or duodenum  
2 Maculopapular rash, 25% – 
50% of body surface a Bilirubin  
3.1–6 mg/dL b 1000 -1499 mL diarrhea/day c 
3 Maculopapular rash,  
> 50%  of body surface a Bilirubin  
6.1–15 mg/dL b 1500 or more mL diarrhea/day c 
4 Generalized erythroderma 
with bullous formation  Bilirubin  
>15 mg/dl b Severe abdominal pain with or without 
ileus  
a Use “Rule of Nines” to determine extent of rash.  
b Range give n as total bilirubin. Downgrade one stage if an additional cause of elevated bilirubin has 
been documented.  
c Downgrade one stage if an additional cause of elevated bilirubin has been documented.  
    
Overall Clinical Grading of Severity of Acute GVHD 
a 
 
 
Grade   
Degree of Organ Involvement  
 
I  
Stage 1 -2 rash and no liver or gut involvement  
 
II  
Stage 3 rash, or stage 1 liver involvement, or stage 1 gut involvement  
 
III  
None to stage 3 skin rash with stage 2 –3 liver, or stage 2 –4 gut involvement  
 
IV  
Stage 4 skin rash, or stage 4 liver involvement  
a Adapted from Thomas ED, Storb R, Clift RA, et al. Bone -marrow transplantation (second of two parts). 
N Engl J Med. April 24, 1975;292(17):895- 902.  
 
  
 
   
 56 
 
 
Appendix 4. Donor Evaluations  
 Organ Transplantation Protocol for Donor Screening  
The initial examination of potential living donors will include: 
 
• Evaluation by appropriate staff psychiatrist.  
 
• 
HLA typing (by Intermediate resolution) HLA -A, B, C, DRB1, DQA1 and DQB1. . B- and T -cell 
crossmatch tests will als o be performed.  
 
• Determination of ABO blood group.  
 
If the donor is found to be mentally suitable and compatible for blood and tissue types, the following will be performed:  
 
• Health history questionnaire  
 
• Physical examination by physician  
 
• Blood tests:  
o Comprehensive metabolic panel  
o Hepatic panel  
o Lipid panel  
o CBC, Diff, Sed Rate,  
o Retic  
o PT, PTT  
o EBV antibodies  
o CMV IgG  
o RPR 
o CMV antibodies  
o Ab to Hep B core Ag, total Hepatitis B surface antigen Hepatitis B surface antibody Hepatitis C antibody  
o HIV I/II screen  
o HTLV1 antibody  
o Blood to QC for monoclonals for chimerism testing  
• Urine tests:  
o Urinalysis  
o Urine culture  
o 24-hour urine collection for total protein and creatinine clearance  
 
• Chest x- ray (PA and LAT)  
• EKG 
 57 
  
 
 Collecting Donor Adverse Events  
 Adverse events related to study procedures will be collected from the time the donor is enrolled until  
10 days after all study procedures have been completed. Adverse events will be followed until they have resolved or until 30 days after the donor terminates from the study , whichever comes first.  
 Reporting Donor Adverse Events  
 All donor adverse events except those ≤ grade 2 will be reported .  
 58 
  
 
Appendix 5: MEDI -507 Dose Preparation Instructions  
 1.  GENERAL INSTRUCTIONS  
 MEDI -507 is provided as a preservative -free, sterile solution at a concentration of  3.75 mg/mL.  
Each single -use vial contains approximately 4 mL of solution (15mg/vial).  
 
 The solution appears clear with occasional protein strands and particles.  
 
 MEDI -507 must be stored between 2° and 8°C (36 –46°F).  
 
 The so lution must not be frozen.  
 2.  DOSE PREPARATION/ADMINISTRATION:  
 
 Select the appropriate number of vials of MEDI -507 required to prepare the patient’s dose.  
 
 MEDI -507 vials should come to room temperature prior to dose preparation.  
 
 Inspect each vial selected for dose preparation.  
 
 To avoid foaming, the vial should not be shaken. A vial should only be used once to prepare a single dose.  
 
 The solution in each vial should be carefully inspected for turbidity. If the solution is not clear, quarantine the vial( s) at refrigerated 2° and 8°C (36 –46° F) temperature for institution drug 
accountability.  
 
 MEDI -507 must be prepared using aseptic technique.  
 
 MEDI -507 must be diluted for intravenous administration in a polyvinyl chloride (PVC) infusion 
bag containing 0.9 % Sodium Chloride for injection. 
 
 Once a patient’s dose is prepared, it must be administered within 24 hours.  
 
 If it is not administered within this interval, a new dose must be prepared.  
 
 The pharmacist or site personnel should slowly draw the calculated dose volume plus 0.5 mL from the vial(s) using an appropriately sized syringe (additional 0.5 mL for priming filter and needle). Attach a 25 mm 0.22 micron Millex GV filter to the syringe, attach a new needle and slowly prime the syringe to the calculated dose volume. The dose volume of MEDI -507 is then 
added to a polyvinyl chloride (PVC) infusion bag containing 0.9% Sodium Chloride, USP.  
 3.  ANCILLARY ITEMS REQUIRED:  
 
 25 mm 0.22 micron Millex GV filter.  
 Polyvinyl chloride (PVC) infusion bag containing 0.9 % Sodium Chloride, USP  
 59 
  
Appendix 6: Long -term results of HLA mismatched combined kidney and bone marrow 
transplantation without maintenance immunosuppression  
 
Tatsuo Kawai M.D., David H. Sachs M.D., Megan Sykes M.D., Ben Spranger M.D., Ryan J Pena M.D., Thomas R. Spitzer M.D., Nina 
Tolkoff -Rubin M.D., Susan L. Saidman, Ph.D., Frederic I. Preffer, Ph.D., Waichi Wong M.D., Brittany Shonts, Sam LoCascio, Heather 
Morris M.D.,  Winfred W. Williams, Jr. M.D., Rex -Neal Smith, M.D., Robert B. Colvin, M.D. and A. Ben edict Cosimi, M.D.  
for the Immune Tolerance Network  
 
Contribution:  
            T atsuo Kawai, A. Benedict Cosimi, David H. Sachs, Megan Sykes, Thomas Spitzer and Robert B. Colvin worked for study 
design, clinical management, data analyses and manuscript w riting.  Nina Tolkoff -Rubin, Waichi Wong, Winfred W. Williams and 
Rex-Neal Smith participated in clinical management. Susan L. Saidman, Fred Preffer, Ben Sprangers, Brittany Shonts, Sam 
LoCascio, Heather Morris performed in vitro assays and data analyses.  
 
Acknowledgement:  
           This research was performed as a project of the Immune Tolerance Network (N01 -AI-15416), an international clinical 
research consortium headquartered at the University of California San Francisco and supported by the National Institute of Allergy and Infectious Diseases and the Juvenile Diabetes Research Foundation. Mechanistic studies were supported by NIH grant RO1 AI084074. No potential conflict of interest relevant to this article was reported. We thank the Clinical Trials Group of the 
Immune Tolerance Network (ITN) and Eleanor Ramos, M.D., for their participation in the planning and conduct of these studies;  
the ITN Drug Withdrawal Committee for their help in determining appropriate conditions and means for withdrawal of 
immu nosuppressive therapy;  
           
 Summary:  
Background:  We report  the long -term results (up to 10 years) of HLA mismatched kidney transplantation without maintenance 
immunosuppression (IS)  following combined kidney and bone marrow transplantation (CKBMT).   
METHODS:  Five previously reported subjects underwent CKBMT after a nonmyeloablative conditioning regimen (NKD03) 
including cyclophosphamide, thymic irradiation, anti -CD2 mAb with or without pre -transplant rituximab. Five subsequent subjects 
received a re vised regimen (ITN036), in which four doses of peri -transplant rituximab were added.  
RESULTS:  All 10 subjects developed transient chimerism becoming undetectable by day 21 without GVHD. Associated with the 
loss of chimerism, 9/10 developed transient acute  kidney injury (AKI) beginning around day 10. Two kidneys failed: one at week 2 
secondary to humoral rejection and one at 6 months secondary to thrombotic microangiopathy. IS was discontinued 8 -14 months 
post -transplant in the remaining 8 subjects.  One developed acute rejection 2 months later and has remained on chronic IS. Five 
of the remaining 7  are off IS with no evidence of rejection for periods of 3 -10 years. In two subjects, treatment with 
mycophenolate mofetil alone was initiated 7 -8 years after IS  withdrawal due to recurrent MPGN in one and probable chronic 
humoral rejection in the other.  Despite in vitro T cell assays showing loss of anti- donor T cell responses by 6 – 15 months after 
transplantation, donor specific antibody (DSA) became detectable  in 4/5 NKD03 subjects. In contrast, DSA has not been 
detectable in the ITN -036 subjects who received more intensified anti -B cell treatment.  
CONCLUSIONS:  Long -term stable tolerance appears inducible despite induction of only transient chimerism via CKBMT .  Our 
observations emphasize the necessity for adequate B cell depletion during the initial 6 months until T cell tolerance is esta blished. 
Observations in both the successful and unsuccessful cases suggest additional modifications of this approach that will lead to the 
development of this approach.  
  Introduction:  
          Short -term results following organ transplantation have been significantly improved by the use of increasingly efficacious 
immunosuppressive agents. However, their chronic use results in significant morbidity, especially from an increased incidence of cardiovascular disease,
1  infection,2  malignancies,3  de novo diabetes4 and other metabolic derangements.  Unfortunately, the 
potent immunomodulatory effects of current therapeutic protocols do not  prevent the development of chronic rejection, despit e 
their a dministration being pushed to toxic levels. Therefore, induction of tolerance, defined as the absence of destructive 
immune responses to a transplanted tissue without ongoing immunosuppressive therapy, remains the ultimate goal of organ transplantation.  
 60 
  
          Since the seminal work reported by Billingham, Brent and Medawar on neonatal tolerance in 1956, numerous tolerance 
induction strategies have been identified in rodents. However, only a very limited number of these have been successfully 
translated  to large animals and even fewer to primates. Among the few protocols that have been applied in humans, induction of 
donor chimerism, either transient or permanent, currently appears to be the most promising strategy to achieve renal allograf t 
tolerance. I nitial results of clinical trials for tolerance induction in three centers have so far been reported.  Using TLI and DBMT, 
the Stanford group reported successful induction of stable chimerism and renal allograft tolerance in HLA identical kidney transplant  recipients.
5,6  More recently, Leventhal et al. at Northwestern have reported use of an intensive conditioning regimen 
and donor hematopoietic stem cells for induction of tolerance in HLA- mismatched kidney transplant recipients.7  Although the 
follow -up is still brief, persistent donor chimerism without GVHD has been reported, allowing weaning from all m aintenance 
immunosuppression by 1 year in half of the patients.            At Massachusetts General Hospital, based on decades -long basic studies in animal models,
8-11  we have app lied combined 
kidney and donor bone marrow transplantation (CKBMT) for induction of allograft tolerance in both HLA matched12-14 and 
mismatched kidney transplant recipients.15  The early results of the initial five mismatched patients who underwent CKBMT have 
been reported.15 We subse quently extended this approach with a revised regimen to five additional patients. We report here our 
observations in this later cohort as well as the longer -term follow- up (up to 10 years) of the previous recipients of HLA 
mismatched CKBMT.  
 METHODS 
Study  Subjects:  10 subjects with end stage renal disease, aged 22- 46, have been enrolled into the studies. All had one HLA 
haplotype -mismatched parent or sibling donors (Table 1).  
 Conditioning Regimen:   The original preparative conditioning regimen (Fig. 1, NKD03) consisted of 60 mg/kg/d of 
cyclophosphamide administered i.v. on days – 5 and – 4 with respect to transplantation; 0·6 mg/kg/dose of humanized anti- CD2 
mAb (MEDI 507, MedImmune Inc., Gaithersburg, MD) on days - 2, -1, 0 and +1; 5 mg/kg cyclosporine A (C yA, Novartis 
Pharmaceuticals Inc., East Hanover, NJ) i.v. on day – 1; and thymic irradiation (700 cGy) on day – 1. Hemodialysis was performed 
before and 14 hours after each dose of cyclophosphamide. On Day 0, kidney transplantation was followed by i.v. infus ion of 
unprocessed donor bone marrow (DBM). Oral CyA (Neoral, Novartis Pharmaceuticals, Inc.) was administered postoperatively at 8 to 12 mg/kg/day with target trough blood levels of 250 -350 ng/ml, then tapered and discontinued over several months.   
The p rotocol was modified after treatment of the third subject (see Results), to include 1) administration of Rituximab, 375 
mg/m²/dose on days - 7 and - 2; and 2) administration of prednisone, 2 mg/kg/d starting on the day of transplantation and then 
tapering ov er the next 10 post -transplant days (modified NKD03). Since subjects treated with this modified NKD03 still developed 
donor specific antibodies (DSA) after discontinuation of immunosuppression, the regimen was further modified (Fig.1) to add t wo 
more doses  of Rituximab (375 mg/m²/dose) on days 5 and 12, more prolonged administration of prednisone until day 20, and 
tacrolimus in place of CyA for the 5 most recently treated subjects (ITN036). Tacrolimus was slowly tapered over several mont hs 
and completely discontinued at 8 months after confirming no rejection by a 6 month protocol biopsy.  All treatment regimens were approved by the Massachusetts General Hospital Institutional Review Board (IRB) and developed in collaboration with the 
Immune Tolerance Network  (ITN).  
Biopsies: Kidney allograft biopsies were taken per protocol at day 0, 6, 12, 24 and 36 months.  Later protocol biopsies were done 
from 5 -8 years (Fig. 2).  Indication biopsies were taken for episodes of graft dysfunction.  All biopsies were process ed for routine 
light microscopy, immunofluorescence (including C4d stains) and electron microscopy by techniques previously reported 
15,16. 
In Vitro Immunologic Assays:  Standard MLR and CML assays were performed using the methods detailed previously.13  LDA to 
quantify cytotoxic T -lymphocyte precursor frequencies and IL -2-producing Th frequencies were performed as described.17 
Detection of donor specific antibodies:  Serially collected pre and post transplant sera samples were tested for the presence of 
HLA antibodies using ELISA kit (LAT Class I & II, One Lambda, Canoga Park, CA).   
RESULTS:   
 61 
  
Study subjects:   
           A total of 10 subjects, age 22 -46, 6 males and 4 females, were enrolled into these studies.  Their original kidney diseases 
include Alport’s syndrome (n=4), polycystic kidney disease (n=2), membrano -proliferative glomerulonephritis (MPGN) type 
1(n=2), reflux uropathy (n=1) and foc al glomerulosclerosis (n=1) (Table 1). The first three subjects (#1 - #3) received the NKD03 
regimen; the next two subjects (#4 and #5) received the modified NKD03 regimen. The last five subjects(#6 - #10) received the 
ITN036 protocol (Fig. 1).  
Induction of transient chimerism:   
            As in the previously reported patients, all additional subjects developed transient multilineage mixed chimerism which 
became undetectable by 2 -3 weeks post -CKBMT.15,18  
Engraftment syndrome and acute kidney injury (AKI):   
           We previously described the cytokine syndrome -like manifestations observed after CKBMT as “engraftment syndrome”.15,16  
In fact, the symptoms have been temporally associated with the loss of peripheral chimerism as well as of the return of hos t-
derived hematopoietic elements. The most troublesome manifestation of this syndrome is acute kidney injury (AKI), which was 
observed after day 10 in all patients except for Subject #1. The biopsies taken during AKI showed severe endothelial injury w ith 
CD8+ T cell infiltration, as reported previously in detail.16  The peak s erum creatinine (Cr.) level ranged from 3·5 to 15·4 mg/dl 
during days 10 -20. Among the nine subjects who developed AKI, three recovered without additional treatment, two with 
Thymoglobulin and plasma exchange, one with Thymoglobulin alone and one with puls e steroid therapy. Two kidney allografts 
failed to recover due to associated humoral rejection (Subject #3) and thrombotic micro -angiopathy (Subject #8).  
Long -term clinical course of subjects in NKD03 (Subjects #1 -5)  
          Initial results, after follo w-up periods of up to 4 years, in the first five patients, were previously reported.15  
As in that report, except for Subject #3, who retrospectively probably had DSA prior to transplant and suffered early graft f ailure 
due to acute antibody- mediated rejecti on, all renal allografts are functional with the longest survival now exceeding 10 years 
(Subject #1). Four protocol biopsies performed in Subject #1 up to 7·5 years after CKBMT showed no evidence of rejection (Fig s. 
3A-C). Subject #2 remained stable until  year 7 following immunosuppression withdrawal (Fig. 2). At that point, urinary protein 
first became detectable. Allograft biopsy revealed no rejection but recurrence of his original disease, MPGN type I (C3 glomerulopathy) (Figs. 3D -F). Mycophenolate mofe til (MMF) monotherapy for recurrent MPGN was initiated after the 8
th year. He 
is currently stable without worsening proteinuria.  Subject #4 received the modified NKD03 regimen (Fig. 1). As previously 
reported, protocol biopsies up to day 731 stained posit ive for C4d,15  but did not have features of active rejection.  However, his 
five- year protocol biopsy revealed glomerular basement membrane duplication by light and electron microscopy with capillaritis 
and continued C4d deposition with minimal interstitial  fibrosis (Fig. 3I). Although his kidney allograft function has remained stable 
with serum Cr of 1·6 -1·9 mg/dl (Fig. 2), proteinuria became detectable after 7 years post -transplant, and a brief course of IVIG 
and ongoing MMF therapy has been recently initi ated.  Subject #5 remained stable for 5 years with no evidence of rejection or 
C4d deposition. Subsequently, after suffering multiple severe episodes of gout, his renal function deteriorated and C4d 
deposition became detectable for the first time in the bio psy at 6 years. He was treated with high dose IVIG (2g/kg) and 2 doses 
of rituximab. After these treatments, his renal function stabilized. A protocol biopsy at 6.3 months showed minimal transplant glomerulopathy (cg1)  (Figs. 3J, K) with negative C4d staining again became negative (Fig. 3L). He is currently doing well without maintenance immunosuppression.  
Clinical course of subjects in ITN036 (Subjects #6 -10) 
           Subject # 6 developed AKI after day 10 but recovered without additional treatment. His  immunosuppression was slowly 
tapered and completely discontinued at 8 months after CKBMT. He is currently doing well more than 3·5 years after transplantation, without ongoing immunosuppression, and with a serum Cr. level of 1·5 mg/dl. A recent biopsy showed no 
evidence of active rejection (Figs.3M and N). There was de novo C4d staining involving peritubular capillaries (Fig.3O), alth ough 
he continued to have no evidence of DSA by ELISA assay. Immunosuppressive therapy for Subject #7 was discontinued at 8 
months. She is currently over 3 years after CKBMT with normal kidney function (serum Cr. 0.8 mg/dl) (Fig. 2) with no evidence  of 
rejection or C4d staining in the 2 year protocol biopsy (Figs. 3P -R). Subject # 8 failed to recover from AKI, and the biopsy 
performed on day 22 revealed arterial intimal matrix expansion with infiltrating mononuclear cells and arterial fibrinoid necro sis 
without C4d deposition in peritubular capillaries. No DSA was detectable.  Differential diagnosis included acute cellular rej ection 
type III versus intra -renal thrombotic microangiopathy, possibly due to tacrolimus toxicity. Tacrolimus was discontinued and three 
 62 
  
doses of anti -thymocyte globulin were administered with MMF. Despite these treatments, her kidney function gradually fai led 
and she was returned to CAPD at 7 months after transplantation. Subject #9 developed transient AKI after day 10 and recovered 
without additional treatment. Her immunosuppression was slowly tapered and was discontinued at 8 months after 
transplantation.  She is currently well at 3 years after CKBMT with normal kidney function (serum Cr. 1·0 mg/dl). The protocol 
biopsy at 2 years showed no evidence of rejection (Figs.3S -U). In Subject #10, kidney function gradually returned to normal by 2 
months after AKI and a 6 -month protocol biopsy did not show rejection. His immunosuppression was discontinued at 8 months. 
One month later, he developed acute pyelonephritis in the kidney allograft with moderately elevated serum Cr. (2·2 from 1·6 mg/dl). This was treated with antibiotics and the kidney function recovered to base line. However, 3 weeks after the resolution of his infection, he developed severe acute cellular rejection (Banff 2B)(Fig. 3V) with no C4d deposition (Fig. 3X).  DSA were n egative. 
He was treated wi th steroid pulses and anti -thymocyte globulin, following which his renal function improved but never fully 
recovered.  A renal biopsy 6 months later showed interstitial and intimal fibrosis without active inflammation (Fig. 3W).  Al though 
he remains well  almost 3 years post -transplant, his compromised kidney function suggests that gradual progression to ESRD is 
likely (Fig. 2).  
In vitro immunological assays  
Anti- donor T cell responses:  
          MLR, CML, CTLp and HTLp assays in NKD03 subjects were previously reported.15,19  All NKD03 subjects developed donor 
specific nonresponsiveness (DSN)  between 3 to18 months. Serial in vitro immunological assays to test anti -donor T cell responses 
were also performed in the four ITN036 subjects who discontinued their immunosuppression.  In these subjects, DSN or donor -
specific hyporesponsiveness (DSH) were observed in MLR by 3 to 18 months (Table 2).  DSN or DSH were also observed by 3 to 18 
months but some responses against the donor returned positive in Subjects #7 and #9. LDA -HTLp also showed DSH by 3 to18 
months, but anti -donor HTLp response was detectable at 18 months in Subject 9.  
Anti- donor B cell responses (Fig. 4B) :  
          DSA has never been detected in Subject #1. DSA was transiently detected only once in Subject #2 with no evidence of rejection.  Anti -HLA class II DSA has been persistently positive in Subjects #4 and #5. DSA in Subject #4 has been associated with 
C4d deposition and glomerulopathy, whereas DSA in subject #5 has been weak with only transient C4d deposition and no rejection (Fig. 3).   
In contrast to NKD03 subjects, no DSA has been detectable in any of the ITN036 subjects by solid phase assays (ELISA).  
B cell depletion(Fig. 4C) : Recovery of CD3-CD19+ cells in two subjects (Subjects #1 and #2) treated with the original NKD03 
regimen was observed by days 50 and 100, respectively.  With two doses of pre -transplant rituximab (modified NKD03), depletion 
of CD3-CD19+ cells was extended to day 150 (Subjects #4 and #5) but complete loss of CD3-CD19+ cells from the peripheral blood 
was not observed. In contrast, peripheral blood CD3-CD19+ cells were <5/mm3 for 6 months in all five ITN036  subjects treated 
with 4 doses of peritransplant rituximab.18  
 DISCUSSION  
           We report here that induction of long -term (up to 10 years) stable renal allograft function without maintenance 
immunosuppression can be reproducibly achieved after induction of transient lymphohematopoietic chimerism in recipients of HLA-mismatched  CKBMT.  Since chimerism is transient, there has been no GVHD observed in our preclinical 
9,10 and clinical 
studies 15, which is a major advantage of this approach for tolerance induction. We hypothesize that the mechanism of tolerance 
induction after transient chimerism in these recipients differs from that observed in murine models, in which chimerism persists 
indefinitely.8,20  Our NHP studies have consistently demonstrated the necessity for DBM engraftment resulting in measurable 
donor chimerism, especially in lymphoid lineages, for induction of tolera nce.9,10,21  We have therefore concluded that the 
mechanism of tolerance induction by mixed chimerism in primates is likely to involve both central and peripheral pathways.  W e 
postulate that initially, donor cells traveling to the thymus lead both to deletion of newly developing T cells and generation of 
regulatory cells which are required to down- regulate any anti -donor responses that were not eliminated at the time when 
chimerism was established.  Consistently, we have demonstrated marked enrichment for Tregs in the first 6 -12 months following 
conditioning in the patients in both of these series (please cite Andreola AJT here) and additional studies are suggestive of  an 
early wave of Treg emigration from the thymus in these patients (B. Sprangers et al, manuscript in preparation). However, we 
have only occasionally, and only in the first year post -transplant, been able to demonstrate augmentation of anti -donor reactivity 
by depleting Tregs for  in vitro assays,19  We therefore postulate that donor -specific Tregs emigrating from the thymus may 
concentrate in the renal allograft itself, and we are currently addressing this possibility in ongoing studies.  However, given the 
complete and long -lasting donor -specific unresponsiveness in Treg -depleted T cells of our patients and the apparent absence of 
donor -specific T cell precursors or of suppressive activity suggested by late LDAs , 19 we have suggested that donor -spec ific T cells 
are ultimately deleted by continual encounter with donor antigens in a non- inflammatory context in the graft.19 
 63 
  
In our monkeys,  costimulatory blockade, with agents directed against CD40/CD15410 or B7/CD28 (manuscript in 
preparation) were helpful in achieving consistent  tolerance.  In our clinical protocol, we have used anti -CD2 monoclonal antibody 
which provides both T -cell depletion and costimulatory blockade via the CD2/LFA -3 interaction 15.  Our studies have also 
emphasized that the kidney allograft itself appears to play a critical role in the induction and maintenance of tolerance. This point 
is illustrated directly by our in vitro studies, in which patients receiving combined kidney and BMT develop donor -specific 
unresponsiveness,15,19  whereas those r eceiving similar BMT regimens in a cancer treatment protocol, without a kidney graft, 
demonstrated preserved anti -donor responses following loss of peripheral blood chimerism.17  Consistently  the same 
conditioning/transient chimerism regimen that  achieves renal allograft tolerance has failed to induce tolerance of isolated heart allograft s in monkeys.
22 Interestingly, heart allograft tolerance can be achieved by co -transplanting the kidney from the same 
donor. and heart allografts that had survived long -term are promptly rejected if the kidney allograft is removed.23 Presumably, 
the donor -specific regulatory cells generated during the chimeric state require continuing interaction with as yet undefined 
specific cells or antigens in the kidney allograft for maintenance of the tolerance. One potentia lly important renal cell is the renal 
tubular epithelial cell, that has been reported to participate in the induction of allospecific tolerance in rodents and huma ns.24-26     
          Despite the encouraging results of successful long -term tolerance induction in our initial clinical trials, several obstacles to 
more widespread application of this approach have been identified. The most troubling of these is the “engraftment syndrome”.  AKI is a major manifestation of engraftment syndrome and has been observed at approximately day 10 in all subjects except for  
Subject #1.  This syndrome has been described previously following both autologous and allogeneic bone marrow 
transplantation, which has been associated with the recovery of either host or donor type  hematopoietic elements 
27.  We note 
that the AKI of engraftment syndrome has never been observed in our MHC -mismatched monkey model, in which chimerism is 
also lo st, but at a more gradual pace, usually over 2 -3 months.9,10,28  Our current interpretation of these findings is that the pre -
transpla nt cyclophosphamide -based regimen chosen for the clinical trials,15  in contrast to the non -myeloablative total body 
irradiation used in the monkey preparative regimen,9,10,28,29  may allow rapid homeostatic recovery of host memory T cells, which 
may be associated with significant effector function, as suggested by the observation of CD8 T cell activation immediately 
following conditioning 16 and rapid rejection of the donor hematopoietic graft.  Further supporting this  hypothesis is the 
observation that AKI has also never been observed in our HLA -matched CKBMT recipients, in whom chimerism as in the NHP 
recipients typically disappears more slowly, over a periods of 2- 3 months.12,14  However, marrow rejection may not be the driving 
force for this syndrome, since C D8 activation is observed as early as Day 0,16 before sensitization cou ld occur. Unfortunately, our 
efforts to test this hypothesis, by using a cyclophosphamide -based regimen in monkeys, have been precluded by unusually severe 
toxicities of this agent in this species.30   
        The second obstacle observed in the first study (NKD03) subjec ts was the frequent development of either transient or 
persistent DSA, despite specific loss of anti -donor T cell responses. In NKD03, DSAs were detectable in most subjects except for 
Subject #1. Despite occasional (Subject #2) or persistent (Subjects #4 a nd #5) detection of DSA, only Subject #4 developed chronic 
glomerulopathy with C4d deposition. Studies are underway to evaluate the possible usefulness of the Luminex approach to identifying DSA complement fixation (C1q) as a means of clarifying the clinical relevance of these variably detected antibody levels in allograft recipients not on chronic immunosuppression. In contrast to NKD03 subjects, with the more intensified anti- B 
cell treatment afforded by adding rituximab to the conditioning regimen for IT N036 subjects, there has been no evidence of DSA.  
Since anti -HLA antibodies are thought to represent T cell -dependent responses, these observations suggest that B cells in NKD03 
subjects might have been sensitized before T cell tolerance was established by mixed chimerism.
15  Since anti - donor HTLp 
responses can be observed up to 18 months after CKBMT (Fig. 4A), it may be critical to prevent B cell activation during the e arly 
post -transplant period in order to establish robust tolerance. Although rituximab does not affect serum immunoglobulin levels, 
antigen -specific antibody titers, or antibody secreting plasma cell numbers, it does effectively deplete peripheral mature B cells, 
likely including germinal center B cells 31. The germinal center is the nidus of immuno logical activation, where close collaboration 
between antigen driven T and B cells occurs 32. Thus B cell depletion by rituximab can prevent humoral immune responses and 
antibody class switching 31 and its use in ITN036 appears to have largely removed this obstacle to tolerance induction via this 
approach.  
          The third obst acle to more widespread application of our tolerance technology is its requirement for living donor 
transplantation, as this strategy involves treatment of the recipient beginning 6 days prior to transplantation. To address this obstacle, we have recently developed a novel regimen for “delayed tolerance” induction, in which the recipient initially 
undergoes organ transplantation with conventional immunosuppression, followed by conditioning and DBM transplantation at a later date.  In our NHP studies,  we have shown that such “delayed tolerance" can be induced by modifying the post -transplant 
treatment to avoid  generation of donor -specific memory T cell responses prior to induction of mixed chimerism 
29,33.  In addition 
to making it possible to utilize deceased donors for renal transplants, successful application of this new procedure could  permit 
 64 
  
treatment of patients with functioning transplants who want to discontinue immunosuppression for a variety of reasons and 
could also help to extend tolerance to other non -renal organs .  
             In conclusion, our clinical studies have shown th at immune -suppression free stable renal allograft function can be 
reproducibly achieved for periods now extending to 10 years by induction of transient chimerism through DBMT. Further modifications of the protocol are planned to address the “engraftment sy ndrome” related AKI, which is the current major barrier 
to continued development of this approach.  
 
Figure Legends  
Fig. 1: Anti -donor responses - T cell responses  
Anti- donor or anti -third party LDA -HTLp in ITN -036 subjects are shown. LDA -HTLp also showed DSH by 3 to18 months, but anti -
donor HTLp response was detectable at 18 months in Subject 9.  1A: Detection of donor specific antibody (DSA)  
DSAs are detected by ELISA.  
NKD03:  Subject #1: DSA has never been detectable. Subject #2: DSA was only transiently detected  once around 7 years.  
Subject 3: Although pre -transplant DSA was negative by ELISA, retrospective Luminex showed positive anti -class I DSA (B44) 
before transplantation. The subject developed acute humoral rejection on day10 with DSA (B44 and DR4).  Subjects 4 and 5: 
DSA became positive soon after stopping his immunosuppression with or without C4d deposition and chronic rejection (See 
Fig.3G -L).  
ITN036: In contrast to NKD03 subjects, No DSA has been detectable in any ITN036 subject.   
 
Figure 2 : CD3-CD19+ cell depletion after CKBMT  
In two subjects treated with the NKD03 regimen, the recovery of CD3-CD19+ cells (B cells) were found by day 50 (Subject #1) 
and day 120 (Subject #2)(black lines). With addition of two doses of pre -transplant rituximab (mod ified NKD03), B cells were 
never depleted completely and recovered by days 150 and 180 (blue lines). With 4 doses of peri -transplant rituximab (ITN036), 
B cells were significantly depleted (less than 1- 2/mm2) for 180 days (red lines).  
 Fig. 3: Late renal allograft biopsies (all protocol biopsies unless noted).  
A-C (Subject #1 at 7.5 years):   The protocol biopsy shows no evidence of rejection by light microscopy (LM) (A).  The glomeruli 
are normal by electron microscopy (EM) (B) and no C4d staining is detectable by immunofluorescence (IF)( C)  
D, E, F (Subject #2 at 8 years): An indication biopsy for proteinuria shows prominent lobular mesangial expansion with widespread glomerular basement membrane (GBM) duplication (D, arrow).  Granular dense deposits in the duplicated GBM 
are seen by EM (E) . Granular and segmental staining for C3 along the GBM and in the mesangium is evident by IF, but no 
immunoglobulin was detected (F),  indicative of recurrent C3 glomerulopathy  (originally classified as MPGN, type I)..   
G,H,I (Subject #4 at 5 years):  Widespread GBM duplication (arrow) and glomerulitis is seen by LM (G).  EM shows prominent 
duplication of the GBM without deposits and reactive endothelial cells (H).  C4d deposition is detected in peritubular capill aries 
(I). These findings are indicative of chronic, active antibody mediated rejection, which at this time was subclinical .  
J,K,L (Subject #5 at 6 years):  The biopsy shows minimal glomerulitis by LM (j), slight segmental GBM duplication by LM (J) and 
EM (K) and no  C4d deposition by IF (L)   
M,N,O (Subject #6 at 2 years):  LM shows normal glomeruli with rare foci of interstitial mononuclear inflammation affecting 
<5% of the cortex.  EM shows minimal focal GBM duplication and normal endothelium (N).  C4d was present i n the majority of 
the peritubular capillaries (O).   
P,Q, R (Subject #7 at 2 years): LM is within normal limits (P).  EM reveals a normal GBM and endothelium; foot process 
effacement is present in a minority of the capillaries (20%) (Q). There is no C4d deposition (R).   
S,T, U (Subject #9 at 2 years):  The kidney biopsy is within normal limits and shows  no evidence of rejection by LM (S) with 
normal glomeruli by EM (T).  There is no evidence of recurrent MPGN.  No C4d is detected (U).   
V,W,X: (Subject #10) : Indication biopsy at 9.5 months shows acute cellular rejection with endarteritis (V).  A protocol biopsy six 
months later shows complete resolution of the inflammatory process and residual interstitial and intimal fibrosis (W).  No C4d 
deposition is dete ctable at 9.5 months  (X) or at other times .  
           Light microscopy stains: H&E, A, M, V; PAS, D, G, J. P, S. Immunofluorescence stains: C4d, C, F, I, L, O, R, U, X.  
 
 
 
 
 65 
  
References  
 
1. Lentine KL, Brennan DC, Schnitzler MA. Incide nce and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol  
2005; 16(2):496-506.  
2. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and 
associated risk  factors. Clin Transplant  2006; 20(4):401- 9. 
3. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, 
malignancy and infection. Drugs 2009; 69(16): 2227- 43. 
4. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest  2000; 23(7):482- 90. 
5. Scandling JD, Busque S, Dejbakhsh- Jones S, et al. Tolerance and chimerism after renal and hematopoietic -cell transplantation. N Engl J 
Med  2008; 358(4): 362-8. 
6. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med 
2011; 365(14): 1359- 60. 
7. Leventhal J, Abecassis M, Miller J, et al. Chimerism and Tolerance Without GVHD or Engraftment Syndrome  in HLA- Mismatched 
Combined Kidney and Hematopoietic Stem Cell Transplantation. Sci Transl Med 2012; 4(124): 124ra28.  
8. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative r egimen. J 
Exp M ed 1989; 169(2): 493- 502.  
9. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 
1995; 59(2):256-62. 
10. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in 
nonhuman primates. Am J Transplant  2004; 4(9):1391- 8. 
11. Sykes M. Mixed chimerism and transplant tolerance. Immunity  2001; 14(4):417- 24. 
12. Spitzer TR, Delmonico F, Tolkoff -Rubin N, et al. Combined hi stocompatibility leukocyte antigen -matched donor bone marrow and renal 
transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed 
lymphohematopoietic chimerism. Transplantation 1999; 68(4): 480-4. 
13. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marr ow 
transplantation: in vivo and in vitro analyses. Am J Transplant  2006; 6(9):2121- 33. 
14. Spitzer TR, Sykes M, Tolkoff -Rubin N, et al. Long -Term Follow- Up of Recipients of Combined Human Leukocyte Antigen- Matched Bone 
Marrow and Kidney Transplantation for Multiple Myeloma With End- Stage Renal Disease. Transplantation 2011.  
15. Kawai T, Cosimi AB, Spitzer TR, et al. HLA- mismatched rena l transplantation without maintenance immunosuppression. N Engl J Med 
2008; 358(4): 353-61. 
16. Farris AB, Taheri D, Kawai T, et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone 
marrow allografts. Am J Transpl ant 2011; 11(7): 1464- 77. 
17. Shaffer J, Villard J, Means TK, et al. Regulatory T -cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell 
transplantation with a humanized anti -CD2 mAb, MEDI -507, with or without fludarabine. Exp Hematol  2007; 35(7): 1140 -52. 
18. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor -specific 
unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance . Transplantation 
2010; 90(12): 1607- 15. 
19. Andreola G, Chittenden M, Shaffer J, et al. Mechanisms of donor -specific tolerance in recipients of haploidentical combined bone 
marrow/kidney transplantation. Am J Transplant  2011; 11(6):1236- 47. 
20. Sykes M, Sach s DH. Mixed chimerism. Philos Trans R Soc Lond B Biol Sci  2001; 356(1409): 707-26. 
21. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achievi ng mixed 
chimerism and donor -specific tolerance in  cynomolgus monkeys. Transplantation 1997; 64(5): 709-16. 
22. Kawai T, Cosimi AB, Wee SL, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. 
Transplantation 2002; 73(11): 1757- 64. 
23. Tonsho M MT, Klarin D, Boskovic S, Nadazdin O, Benichou G, Cosimi AB, Smith NR, Colvin RB, Kawai T, Madsen JC. . Induction of 
Tolerance to Heart Allografts by Donor Kidney Co- Transplantation in Nonhuman Primates (NHPs). . American Transplant Congress 2012  
2012, Boston: 157.  
24. Braun MY, McCormack A, Webb G, Batchelor JR. Evidence for clonal anergy as a mechanism responsible for the maintenance of  
transplantation tolerance. Eur J Immunol  1993; 23(7):1462 -8. 
25. Frasca L, Marelli- Berg  F , Imami N, et al. Interferon -gamma -treated  renal tubular epithelial cells induce allospecific tolerance. Kidney Int  
1998; 53(3):679-89. 
 66 
  
26. Starke A, Lindenmeyer MT, Segerer S, et al. Renal tubular PD -L1 (CD274) suppresses alloreactive human T -cell responses. Kidney 
Int;78(1): 38-47. 
27. Spitzer TR.  Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant  2001; 27(9): 893- 8. 
28. Kawai T, Poncelet A, Sachs DH, et al. Long- term outcome and alloantibody production in a non- myeloablative regimen for induction of 
renal allograft tolerance. Transplantation 1999; 68(11): 1767 -75. 
29. Yamada Y, Boskovic S, Aoyama A, et al. Overcoming Memory T -Cell Responses for Induction of Delayed Tolerance in Nonhuman 
Primates. Am J Transplant  2012; 12(2):330- 340.  
30. Sogawa H, Boskovic S, N adazdin O, et al. Limited efficacy and unacceptable toxicity of cyclophosphamide for the induction of mixed 
chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 2008; 86(4): 615-9. 
31. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Mainten ance of long -lived plasma cells and serological memory despite mature and memory B 
cell depletion during CD20 immunotherapy in mice. J Immunol  2008; 180(1): 361-71. 
32. Parsons RF, Vivek K, Redfield RR, 3rd, et al. B -lymphocyte homeostasis and BLyS -directed immunotherapy in transplantation. Transplant 
Rev (Orlando) ;24(4): 207-21. 
33. Koyama I, Nadazdin O, Boskovic S, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously trans planted kidney 
allograft. Am J Transplant  2007; 7(5):1055-6 1. 
 
 
 
        
 
        
 
         
 
   
 67 
  
Fig. 1
 
 
pre 1 y 2 yrs 3 yrs 4 yrs 5 yrs 6 yrs 7 yrs 8 yrs 9 yrs 10 yrs
#1 - - - - - - - - -
#2 - - - - DQ9 -
NKD03 #3 - DR4
#4 - - DR17 DR17 DR17 DR17
#5 - - - DR53 DR53 DR53 DR53
#6 - - - - -
#7 - - - - -
ITN036 #8 - -
#9 - - - -
#10 - - - -Fig. 1A
 
 68 
  
Fig. 2
 
A B C D E F
G H I J K L
N O PFig. 3
M
 Q
S T U
 X V WR
K
 
 
 
 
     
 69 
  
Appendix 7: Schedule of Events for Safety Follow -up 
1 Can discontinue GVHD assessment once chimerism is not detectable.  
2 Perform test until chimerism is no longer detectable. Chimerism testing will be done by Flow Cytometry. In the event 
that HLA antigens (needed for Flow cytometry analysis) cannot be detected by available monoclonal antibodies, 
STR/Microsatellite methodology will be used.  
 Time           M6  Y1    Y2 
Week  0 2 6 8 10 13 14 18 22 26 39 52 65 78 91 104 
Follow -up for participants prematurely discontinued from study therapy (section 3.4.4.2)  
Visit   101 102  103  104 105 106 107 108 109 110 111 112 113 
Assessments                  
Adverse events   X X  X  X X X X X X X X X X 
Concomitant medications   X X  X  X X X X X X X X X X 
Physical examination   X X  X  X X X X X X X X X X 
Hematology   X X  X  X X X X X X X X X X 
Serum and basic 
  X X  X  X X X X X X X X X X 
Thyroid function   X X  X  X X X X X X X X X X 
GVHD assessment1  X X  X  X X X X X X X X X X 
Graft survival   X X  X  X X X X X X X X X X 
Chimerism2  X X  X  X X X X X X X X X X 
Follow -up for participants prematurely terminated from study (section 3.5.2)  
Visit  201   202             
Assessments                  
Adverse events  X   X             
Concomitant medications  X   X             
Physical examination  X   X             
Hematology  X   X             
Serum and basic 
 X   X             
Thyroid function  X   X             
GVHD assessment1 X   X             
Graft survival  X   X             
Chimerism2  X   X             
Follow -up treatment for participants who fail immunosuppression withdrawal (section 4.4.8.5)  
Visit  301     302    303 304 305 306 307 308 309 
Assessments                  
Adverse events  X     X    X X X X X X X 
Concomitant medications  X     X    X X X X X X X 
Physical examination  X     X    X X X X X X X 
Hematology  X     X    X X X X X X X 
Serum and basic 
 X     X    X X X X X X X 
Thyroid function  X     X    X X X X X X X 
GVHD assessment1 X     X    X X X X X X X 
Graft survival  X     X    X X X X X X X 
Chimerism2  X     X    X X X X X X X 
 70 